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 Acan   Aggrecan gene 
BMP   bone morphogenetic protein  
CD-RAP   cartilage-derived retinoic acid-sensitive protein  
CEC    chicken embryo chondrocytes 
CEF    chicken embryo fibroblasts  
Col2a1   collagen-2 gene 
 DMEM   Dulbecco’s modified Eagle’s medium  
 Dpe1 and Dpe2  distal elements 1 and 2 
 DTT    dithiothreitol  
 ds   double stranded 
 ECM   extracellular matrix  
EMSA   electrophoretic mobility shift assay 
 FCS   fetal calf serum  
 GST    glutathione S-transferase 
GTF   general transcription factor 
HDM   high-density mesenhyme 
 HMG    high-mobility group   
 Ine    initiator element  
 IPTG    isopropyl--D-thiogalactopyranoside  
 MATN1/Matn1  matrilin-1 (human/other vertebrate) 
 Matn2   matrilin-2 (human/other vertebrate) 
 MATN3/Matn3  matrilin-3 (human/other vertebrate) 
 MED   multiple epiphyseal dysplasia 
 NFI/Nfi  nuclear factor-I (human/other vertebrate) 
 PAGE   polyacrylamid gel electrophoresis  
 Pe1   promoter element 1  
 PIC   preinitiation complex 
 PMSF   phenylmethylsulphonylfluoride  
 SF-1   steroidogenic factor-1  
 SI and SII  silencer element I and II  
 Sox    sry-type HMG box protein 
 Sry   sex-determining region Y 





2.1. Cartilage and chondrogenesis 
 
2.1.1. Endochondral bone formation   
Endochondral ossification is a multistep process, which involves spatiotemporally strictly 
regulated morphogenetic and differentiation steps [1, 2]. It leads to the formation of most of the 
skeletal elements during vertebrate embryonic development and it takes place also in the growth 
plates, where it is responsible for longitudinal bone growth till adulthood. During endochondral 
ossification mesenchymal precursors differentiate into bone tissue through replacement of a 
cartilaginous intermediate. 
Chondrogenesis starts with the condensation and commitment of mesenchymal precursors 
and their differentiation to prechondrocytes in a shape prefiguring the future bones (Fig 1). The 
prechondrocytes subsequently differentiate into early chondroblasts, which proliferate, form 
columns and deposit an extensive cartilaginous extracellular matrix (ECM) serving as template of 
the future bones. Then, starting from the middle of the cartilaginous primordia, proliferative 
chondroblasts exit from the cell cycle and successively undergo prehypertrophic and 
hypertrophic development [3, 4]. Finally blood vessels, osteoclasts and osteoblasts invade and 
replace the mineralized hypertrophic cartilage by bone tissue. Growth plates are formed at the 
end of long bones by chondrocytes organized into distinct zones according to their differentiation 
stages. During fetal and postnatal development, bones elongate as the cells proliferating in the 
columnar zone progress through the prehypertrophic and hypertrophic zones, and eventually the 
calcified ECM laid down by terminally differentiated cells is used as a scaffold by osteoblasts to 
deposit bone ECM.  
Chondrogenesis is directed by three master transcription factors, Sox9, L-Sox5 and Sox6, 
called the Sox trio (Fig 1) (see later 2.2.3.) [5]. Numerous autocrine, paracrine and endocrine 
factors determine the shape and size of skeletal elements often acting by modulating the 
expression or the activity of the Sox trio. Maintenance of proliferation in the columnar zone and 
bone growth depends on positive and negative feed back loop formed between Ihh (Indian 
hedgehog) and PTHrP (parathyroid hormone-related protein) and affected by growth factors 
(FGF, BMP), hormones and various other signaling pathways [2, 3, 6]. Stimulation of 
chondrocyte proliferation by mechanical load is mediated by Ihh via BMP signaling [7]. On the 
other hand, induction of Ihh expression in the prehypertrophic zone, hypertrophic differentiation 
and ossification is regulated by Runx2, the master factor of the osteoblast lineage [6]. In addition, 
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Hmgb1 secreted by hypertrophic growth plate chondrocytes is needed for cell invasion to 
function as a chemoattractant for osteoclasts, osteoblasts and endothelial cells [8].  
 
 
Fig. 1. Chondrogenesis. Stages of chondrocyte differentiation are shown indicating the up- and down-
regulation of important marker genes by green and yellow arrows, respectively. Role of Sox transcription 
factors in the regulation of differentiation steps is also indicated. 
 
 
2.1.2. Gene expression during chondrogenesis 
The cartilaginous ECM consists mainly of proteoglycans, collagens and non-collagenous 
multiadhesion proteins. While the major constituent, collagens and the proteoglycan-hyaluronan 
aggregate determine the physical properties of the cartilaginous ECM, other components are 
responsible for the diversity among growth plate zones and cartilage forms. The collagen fiber 
network comprised of collagen-2, collagen-9 and collagen-11 is responsible for the high tensile 
strength of cartilage. The collagen network in cartilage entraps a highly hydrated gel of 
proteoglycans and glycoproteins giving high resilience to cartilage against compression and shear 
forces. Aggrecan (Acan) is the most abundant proteoglycan that is almost unique to cartilage. 
Acan molecules form enormous aggregates by binding to linear chains of the glycosaminoglycan 
hyaluronan with the help of cartilage link protein (Crtl1). Glycoproteins, such as matrilins, 
cartilage oligomeric matrix protein (Comp) and small proteoglycans, such as fibromodulin, 
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decorin and biglycan, vary in abundance according to the types of cartilage. Collagen-10 is 
produced in abundance exclusively by prehypertrophic and hypertrophic chondrocytes. 
Matrilins are multidomain filament-forming proteins, which function as adaptor proteins in 
the ECM assembly and in mechanotransduction of chondrocytes [9-11]. Matrilin-1 (Matn1) was 
formerly called CMP (cartilage matrix protein) as it is expressed exclusively in chondrocytes, 
while Matn2, Matn3 and Matn4 are also found in other tissues. By binding many ECM 
components, Matn1 can mediate connections between Acan, collagen-2 fibers and collagen-6 
beaded filaments. Lack of functional Matn1 and Matn3 in the pericellular matrix was reported to 
interfere with Ihh signaling and mechanical stimulation of chondrocyte proliferation and 
differentiation [12].  
Chondrogenesis is accompanied by sequential changes in the ECM gene expression and in 
the ECM composition [3, 13, 14]. Thus prechondrocytes start to express Col2a1 (collagen-2 
gene), whereas genes for aggrecan (Acan), minor collagens (e.g. Col9a1) and non-collagenous 
proteins (e.g. Crtl1) are turned on in early chondroblasts and activated further in columnar 
chondroblasts. Matn1, however, has a narrower expression pattern in both space and time than 
other ECM genes [14-17]. In particular, its expression is restricted to the columnar and 
prehypertrophic growth plate zones playing important roles in bone growth [18-20]. In 
chondrogenic cultures, it showed a delayed activation in early proliferative chondroblasts as 
compared to other cartilage ECM genes and had a high activity only in late proliferative 
chondroblasts [16]. During terminal differentiation, the cartilage-specific genes are turned off, 
while Col10a1 (collagen-10 gene) is turned on. 
 
2.1.3. Effect of ECM gene mutations in animal models of human diseases 
Lack or mutations of genes encoding the major ECM components, which determine the main 
physical properties of cartilage, such as collagen-2, Acan and Crtl1, cause serious or lethal 
diseases. Thus, null mutation for COL2A1/Col2a1 leads to lethality or severe abnormalities in 
both human and mouse skeletal development [21]. This disease is called achondrogenesis type II, 
which is characterized by short limbs, ribs and trunk and domed skull in collagen-2-null mice 
[22]. In addition, glycine mutatitions in collagen-2 generate a range of chondrodysplasias, 
including spondyloepiphyseal dysplasia, Kniest dysplasia, hypochondrogeneis and Stickler 
syndrome (premature osteoarthritis) [22, 23]. A 7-bp deletion in Acan leading to stop codon in 
exon 6 caused cartilage matrix deficiency (cmd) in the mouse [21], in the animal model of lethal 
human chondrodysplasia. Homozygous mice for cmd die at birth and suffer from 
disproportionate dwarfism, clef palate, short snout and protruding tongue. Targeted inactivation 
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of Crtl1 in transgenic mice revealed the essential role of the protein in cartilage development. 
Most homozygotes died shortly after birth due to respiratory failure and the few survivors 
developed progressive drawfism, craniofacial abnormalities and lordosis of the cervical spine. 
They showed characteristics of spondyloepiphyseal dysplasias, such as small epiphysis and 
flattened vertebrae [24]. 
Mutations in other cartilage proteins involved in the ECM assembly or disruption of their 
genes have less dramatic effects in animal models. For instance, mice deficient in matrilin family 
members are viable under laboratory conditions [10]. Matn1 upregulation was implicated in 
vertebral fusion of Atlantic salmon [25]. A linkage of MATN1 was reported to osteoarthritis in 
the Dutch population [26]. Various polymorphism of MATN1 was found to predispose to 
idiopathic scoliosis in Asian and Turkish population [27]. MATN1 polymorphism was also linked 
to mandibular prognatism in human [28]. MATN1 was clearly associated to relapsing 
polychondritis, a rare autoimmune disease. Circulating MATN1 antibodies were found to 
function as autoantigen in these patients, and immunization of mouse or rat with MATN1 caused 
similar symptoms in an animal model of this human disease [29, 30].  
Among matrilins, a close association with human diseases has been best characterized for 
MATN3. Mutations in MATN3 caused a severe disease referred to as pseudoachondroplasia 
(PSACH) or a milder form called multiple epiphyseal dysplasia (MED). These are characterized 
by moderate disproportionate dwarfism and musculoskeletal alterations. In the milder forms of 
MED mutations were identified in MATN3 or collagen-9 genes (COL9A1, COL9A2, COL9A3), 
whereas the severe form was caused by mutations in COMP (cartilage oligomeric matrix protein 
gene) [31]. More than 20 different mutations within Matn3 were connected to autosomal-
dominant MED. A mouse model of MED caused by a Matn3 V194D mutation replicated the 
human phenotype [32]. Homozygous mice for this mutation are normal at birth but from day 14 
they develop a measurable short-limbed dwarfism as a result of disturbed endochondral 
ossification. Interestingly, when mice with a Matn3 V194D mutation were crossed with Matn1-
null mice, aggravation of the skeletal phenotype was observed [33].  
Matn2-/- mice do not show obvious skeletal abnormalities [34], but they serve as a good 
animal model of DEN-induced hepatocarcinogenesis [35, 36]. This animal model is suitable to 
assess the efficacy of antitumor drugs [37]. Matn2 also plays a role in myogenesis timing during 





2.2. Transcriptional control of tissue-specific gene expression 
 
2.2.1. Players of eukaryotic transcription 
In eukaryotes, the template for mRNA transcription is not free DNA, but chromatin. This is 
the highest level of eukaryotic gene regulation, and chromatin has a major regulatory role in 
development. The chromatin contains histone and non-histone components. The core histones 
(H2A, H2B, H3 and H4) package the DNA to make up the basic chromatin unit, the 
nucleosomes, which are linked by histone H1, the linker histone and assembled into higher-order 
structure Gene activation requires various chromatin remodeling processes to open the 
compacted chromatin into a relatively extended state and to expose specific DNA sequences so 
that these can be targeted by the RNA polymerase II (PolII) machinery and transcription factors 
involved in the process of gene transcription.  
The non-histone chromatin components function as architectural factors in the organization 
and fluidization of the chromatin by appropriately bending and plasticizing DNA. For instance, 
the high mobility group (HMG) proteins belong to three families based on their DNA-binding 
domains. Hmga proteins interact with AT-rich sequences in the minor groove of the DNA by 
their AT-hook HMGA domain. Hmgb proteins bind DNA without sequence specifity in the 
minor groove by their L-shaped HMG box (HMGB) domains. Hmgn proteins directly interact 
with nucleosomes via their nucleosome-like HMGN domain. HMGBs better bend the DNA than 
transcription factors that bind DNA in the major groove. 
Transcriptional control represents the second, best characterized level in the spatio-
temporal regulation of gene expression. Transcription occurs as a result of interplay between cis-
acting DNA elements and trans-acting factors. The cis elements include the core promoter, 
promoter-proximal and distal control elements (e.g. enhancers and silencers), which carry 
binding sites for various trans-acting factors. Apart from PolII, trans-acting factors include 
general transcription factors (GTFs) (TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH), associated 
factors (TAFs), the mediator complex and classical transcription factors. A typical core promoter 
features a TATA box 25-30 bp upstream of the transcription start site. The TATA box is 
recognized by the TATA-binding protein (TBP) of the TFIID complex, whereas TAFs and PolII 
interact with the initiator element.  
The general transcription machinery consisting of PolII, GTFs and the mediator complex can 
assemble on the core promoter and form a preinitiation complex (PIC), but it can drive only a 
basal level of transcription. Classical transcription factors (e.g. NFI, IL1, HOX and POU 
proteins) recognizing proximal and distal control elements are required for activated or regulated 
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transcription to increase the efficiency of initiation. They bind short DNA motifs in the major 
groove of DNA with high sequence specificity and high affinity. Based on their DNA binding 
domains, we distinguish zinc finger, helix-loop-helix, helix-turn-helix, leucine zipper and 
homeodomain proteins. The classical or typical transcription factors also feature activation or 
repression domains and by interacting with GTFs (e.g. TFIIA) they can either serve as activators 
by activating transcription, or as repressors by inhibiting transcription [39]. The classical 
transcription factors often have dimerization domain and they may function as cell type-specific 
or ubiquitous factors. They often bind in a cooperative manner to nearby DNA elements.  
According to latest scientific results, there are trans-acting factors, which represent a 
transition between architectural HMG proteins and classical transcription factors. For instance 
the Sry-related high mobility group box (Sox) proteins play critical roles in cell fate and 
differentiation decisions in various lineages [3, 40, 41]. Whereas Hmgb proteins are the most 
abundant non-histone chromatin components, Sox proteins are expressed at a low level and only 
in certain cell types. They bind DNA via their HMGB domain in the minor groove with low 
affinity and sequence specificity, but with lower sequence specificity and lower binding 
efficiency (Kd~10
-9-10-11) than classical transcription factors (Kd~10
-7-10-9). Like Hmgb proteins, 
Sox factors also bend the DNA as architectural proteins, thereby facilitating the binding of other 
factors. Some of them have activation or repression domain and can directly influence 
transcription like classical transcription factors. 
Proximal and distal cis-control elements are critical players of tissue-specific gene regulation. 
The proximal DNA elements can function in one orientation and only within a few hundred bp 
from the TATA box. They usually have binding sites for some ubiquitous and tissue-specific 
factors. By contrast, enhancers and silencers highly activate or repress transcription, 
respectively, over large distances and independent of orientation. They usually carry an array of 
recognition motifs for a unique set of transcription factors, which bind in a cooperative manner 
and interact with each other and other factors and GTFs bound to proximal DNA elements and 
the core promoter. Thus, enhancers perform a crucial function in the formation of stereospecific 
nucleoprotein complexes, the enhanceosomes, which modulate transcription via very complex 
protein-protein and protein-DNA interactions. Tissue-specific gene regulation is based on a 
combinatorial interaction between cis-acting elements and trans-acting factors. Apart from 
classical transcription factors, recent data underline the important role of SOX proteins and 





2.2.2. Role of Hmgb1 in gene regulation, development and disease 
Hmgb proteins are very abundant chromatin components. They consist of an acidic tail and 
two L-shaped archetypal HMG-boxes, which bind distorted DNA (bent, kinked, four-way 
junctions) without sequence specificity and only transiently [42-45]. Lacking transactivation 
domain, they act only as architectural proteins to alter the chromatin structure and modulate 
transcription. Hmgb1, which is only 10 times less abundant than core histones, can promote the 
transcription of genes by several mechanisms. It interacts with nucleosomes via its acidic tail and 
loosens the nucleosome structure by displacing histone H1 due to competition for closely 
juxtaposed binding sites on linker DNA [44, 46]. Thus fluidizing the chromatin, Hmgb1 can 
increase the accessibility of chromosomal DNA to regulatory factors. By bending the promoter, it 
helps recruit TBP and other GTFs [43]. By bending the DNA and making protein-protein 
interactions, Hmgb1 can enhance and stabilize the binding of various transcription factors (e.g. 
steroid receptor, Hox and Pou proteins) to their cognate sites and promote the recruitment of 
additional interacting factors. 
Hmgb1 performs diverse architectural and extracellular function in health and disease. In the 
nucleus, it regulates chromatin architecture, transcription, replication and repair processes. In 
addition, Hmgb1 secreted by macrophages and necrotic cells also performs various intracellular 
and extracellular activities as an alarmin, a danger signal during injury and diseases, such as 
infection, inflammation, arthritis and cancer [47].  Hmgb1 was also implicated recently in 
skeletal morphogenesis [48] and in the regulation of late steps of endochondral ossification [8], 
but its role in early steps has not been investigated yet. 
 
2.2.3. Role of Sox proteins in cell fate determination and tissue-specific gene regulation 
Sox proteins play critical roles in cell fate and differentiation decisions in various lineages [3, 
40, 41]. Differing from Hmgb proteins, Sox proteins have low abundance and contain a single, 
Sry-related, non-canonical HMG-box, which binds DNA in the minor groove with low affinity 
and loose sequence specificity [49]. They recognize the A/TA/TCAAA/T motif. Sox factors 
likely bend the DNA as architectural proteins to facilitate the binding of other factors. Some (e.g. 
Sox9) can directly influence transcription via their activation/repression domain and pair off with 
various transcription factors. They interact with many partner factors to facilitate enhanceosome 
formation and control cell fate and differentiation during vertebrate development [50]. Sox 
proteins are encoded by 20 genes and classified into 8 groups based on the similarity of their 
HMGB domains. Sox factors play crucial role in the development of various organs during 
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embryogenesis. For example Sry and Sox9 function in sex determination, Sox1, Sox2 and Sox3 
are involved in eye development and neurogenesis, whereas Sox4, Sox11 and Sox7 have been 
implicated in cardiogenesis [50]. Three Sox proteins (Sox9, L-Sox5 and Sox6), the so called Sox 
trio play a well established role in endochondral bone formation by defining the chondrocyte 
lineage, regulating chondrogenesis and turning on cartilage-specific genes (Fig. 1) [50] Sox9 
serve as a master regulator of the chondrocyte lineage [51]. It is expressed from mesodermal 
precusor cells to the prehypertrophic chondrocyte stage. It directs the commitment of 
osteochondroprogenitors and their differentiation to prechondrocytes. Sox9 is required for the 
aggregation of mesodermal precursor cells and it turns on the genes for L-Sox5 and Sox6 and 
they together direct subsequent steps of chondrogenesis (Fig. 1). Sox9 is also required for the 
activation of cartilage protein genes such as Col2a1, Col9a1, Col11a2 and Acan [52, 53]. 
The first clue that Sox9 plays a role in chondrogenesis came with the identification of 
heterozygous mutations in the SOX9 gene in human patients with camptomelic dysplasia (CD), a 
severe form of chondrodysplasia that is often associated with XY sex reversal and malformations 
in several internal organs [54, 55]. In addittion, Sox9 pairs off with steroidogenic factor 1 to 
regulate transcription of the anti-Muellerian hormone (AMH) gene involved in sex determination 
[56].  
L-Sox5 and Sox6 are expressed in early proliferative chondroblasts and they are required for 
the differentiation of early chondroblasts to late proliferative or columnar chondroblasts in the 
growth plate. L-Sox5 and Sox6 are also needed for the activation of some of the cartilage ECM 
genes (Comp, Matn1) and for the high activity of others (Col2al, Acan, etc.) L-Sox5 is a longer 
product of the Sox5 gene. It is chondrocyte-specific splice variant and highly similar to Sox6. 
Sox5-null and Sox6-null mice are born with minor cartilage defects, whereas the double-null 
mice develop a severe, generalized chondrodysplasia and die around embryonic day 16.5 [57]. 
Respectively, these mice have impairment of chondroblast proliferation and expression of 
cartilage matrix genes. Interestingly, L-Sox5 and Sox6 are required to turn on Matn1, as Matn1 
mRNA was not detected in Sox5-/-; Sox6-/- mice (Fig. 1) [57].  
 
2.2.4. Role of Nfi proteins in development and tissue-specific gene regulation 
Nuclear factor I (NFI/Nfi) is a family of closely related transcription factors, also known as 
CTF or CAAT box transcription factors. CTF/NFI is constitutively active classical transcription 
factor which binds to the CCAAT box motif in the DNA major groove [39]. NFI family members 
play diverse roles in adenovirus DNA replication [58] and transcriptional regulation of viral and 
eukaryotic genes as activators or repressor [59]. They are composed of N-terminal DNA-
 12
binding/dimerization domain and C-terminal, proline-rich transcriptional activation or repression 
domain [60, 61]. They bind to the consensus sequence TTGGC(N5-7)GCCAA) as both 
homodrimers and heterodimers [59, 62]. In vertebrates, the protein family is composed of four 
members Nfia, Nfib, Nfic and Nfix encoded by four different genes located on three 
chromosomes in mammals. The expression patterns of the four Nfi genes overlap during mouse 
embryogenesis [63]. Nfi proteins play relevant role in brain, lung, tooth and skeletal muscle 
development [64-68]. In addition, Nfib has been implicated in early stage of chondrogenesis and 
in the regulation of Col2a1 transcription [69]. Further, NFI proteins can activate transcription 
through direct interaction with basal transcription factors (TFIIB and TBP) [70, 71], various 
coactivator or corepressor factors [72] and histone proteins (H1 and H3) [60, 73] via their 
proline-rich transactivation domain. 
 
 
2.3. Regulation of cartilage-specific gene expression  
 
2.3.1. Role of the Sox trio in the transcriptional regulation of cartilage ECM genes  
The Sox trio plays essential role in the transcriptional regulation of cartilage protein genes. 
Sox9, L-Sox5 and Sox6, besides specifying other lineages, are required and sufficient to induce 
chondrogenesis and cartilage gene expression [50, 53, 57, 74]. Sox9 binds and activates 
cartilage-specific enhancers in Col2a1 [75], Col11a2 [76] and CD-RAP [77]. Besides a DNA-
binding HMGB domain, Sox9 also contains a transactivation domain and a DNA-dependent 
dimerization domain similarly to other members of Group E Sox proteins. Group D Sox proteins, 
L-Sox5 and Sox6 have no transactivation domain and coiled-coil domain mediates their homo- 
and heterodimerization [49].  
The 48-bp intronic enhancer element was identified in the first intron of Col2a1 [75], which 
contains three Sox binding site [52]. These elements bind SOX9, L-Sox5 and Sox6 in a 
cooperative manner [52]. Multiple copies of this element enhanced homologous and heterologous 
promoter activity in the developing cartilaginous skeletal elements of transgenic mouse embryos 
[78]. This DNA element is sufficient to drive cartilage-specific gene expression [75]. The 
COL9A1 enhancer contains two tandem pairs of consensus Sox motifs. SOX9 binds to the 
enhancer and two interdependent dimers are required for transcriptional activation [79, 80]. The 
new collagen gene COL27A1 also carries SOX9-responsive enhancer elements involved in the 
transcriptional regulation of the gene [81]. Sox consensus binding sites activated by SOX9 were 
also found in the cartilage-derived retinoic acid-sensitive protein gene (CD-RAP) [77]. The 
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enhancer and other cis elements from the Col11a2, Col27A, Col2a1, Col9a2 and CD-RAP 
contain two Sox motifs arranged in opposite orientation to each other and separated by 3 or 4 bp 
[77, 78, 81-83]. Sox9 binds as a homodimer, but L-Sox5 and Sox6 bind as a heterodimer to these 
binding sites [49, 83]. In contrast, the non-cartilage-specific enhancers from the Steroidogenic 
Factor I (SFI) and the anti-Mullerian hormone genes (AMH) contain one SOX9 binding site and 
they are activated by SOX9 as a monomer and only [83]. Thus, dimerization of SOX9 is required 
for chondrogenesis, but not for sex determination and gonad development [83]. 
L-Sox5/Sox6 synergize with Sox9 in the transcriptional control of Col2a1 and Acan [52, 84]. 
However, it is far from being understood, how the same Sox trio can exert distinctive regulation 
to other cartilage protein genes with markedly different spatio-temporal expression pattern during 
skeletogenesis.  
 
2.3.2. Transcriptional regulation of Matn1  
Previously, our group cloned the gene for the chicken Matn1 [85]. This gene is 18 kb long 
and comprises 8 exons and 7 introns [85]. The chicken Matn1 promoter contains a TATA motif, 
TTAATA, which can function as a minimal promoter in transient expression assay [85]. The 
Matn1 promoter exhibited chondroblast stage-specific activity in transient transfections [86, 87].  
 
 
Fig. 2. Map of conserved control elements of the chicken Matn1and their functional analysis in 
transgenic mice. (A) The schematic of the Matn1 promoter region illustrates the intiator element (Ine), 
the silencer elements (SI and SII), the proximal promoter element (Pe1) and distal promoter upstream 
elements (Dpe1 and Dpe2). Transcription factors binding to the conserved elements are represented by 
factor names. (B and C) Map of the constructs and functional analysis of the short (B) and long promoter 
(C) in transgenic mice. 
 
 
The chicken Matn1 exhibited a characteristic zonal expression pattern in the developing 
skeleton of transgenic mice [20]. The transgene expression was restricted to the zones of 
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columnar proliferating chondroblasts and prehypertrophic chondrocytes of growth plate cartilage. 
The 2-kb Matn1 promoter with or without the intronic enhancer also directed zonal transgene 
expression. Resembling to the expression pattern of the endogenous Matn1, LacZ expression was 
highest in the columnar and prehypertrophic growth plate zones and it exhibited proximo-distal 
differences in the developing skeleton of transgenic mice (Fig 2C) [20]. The 334-bp short 
promoter with the intronic enhancer showed low activity, but of similar pattern, whereas the short 




Fig. 3. Conservation of DNA elements in the Matn1 promoter in amniotes. Sequence alignments of 
the promoter in the vicinity of the TATA box and Ine (A), the Pe1 (B) and Dpe1 elements (C) are shown 
from a few mammalian species and the chicken. Numbers indicate positions from TATA. Arrows and 
dotted arrows indicate inverted Sox motifs similar to the preferred Sox9-binding site and the Sox 
consensus, respectively. The most conserved motif of Ine is boxed. Conserved motifs similar to the Nfi 
consensus sequence TTGGC(N5-7)GCCAA appear in green.  
 
 
The long (2-kb) Matn1 promoter region features several sequence blocks which are highly 
conserved in amniotes (Fig2A and 3) [19, 85, 86]. These include the most highly conserved 
proximal promoter element 1 (Pe1), which was previously identified by our group in the short 
promoter. It was reported that Pe1 is recognized by the Sox trio, whereas the silencer elements SI 
and SII bind Nfi proteins [87] (Fig. 2B). Furthermore, the 2-kb long Matn1 promoter also 
includes two conserved distal promoter elements, distal promoter element 1 (Dpe1) and distal 
promoter element 2 (Dpe2) (Fig.2A). In transient expression assay, multiple copies of the Dpe1 
element robustly increased the short promoter activity in CEC culture [88]. Eight copies of Dpe1 
fused to the short promoter directed zonal transgene expression of high level in distal structures 
of the developing skeletal elements in transgenic mice [88]. 
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3. AIMS OF THE STUDY 
 
Among the cartilage protein genes, Matn1 has a unique expression pattern, restricted to 
certain chondrocyte developmental stages and distinct zones of the growth plate. This suggests 
that regulation of the Matn1 may involve similar as well as different molecular mechanism as 
compared to other cartilage protein genes, e.g. Col2a1. To get insight into the common and 
distinct molecular mechanisms controlling cartilage-specific gene expression, we aimed to 
identify DNA elements and uncover the role of transcription factors in the transcriptional 
regulation mechanism of Matn1. 
 
The following specific goals were set out:  
1. We planned to study the contribution of the Sox trio, Nfi and Hmgb1 proteins to the 
transcriptional activity of the Matn1 promoter. 
2. We planned to verify that the conserved Dpe1 element is operable as an enhancer. 
3. We planned to study the role of Hmgb1 in the early steps of chondrogenesis. 




4. MATERIALS AND METHODS 
 
4.1. Cell culture  
Chicken embryo chondroblast (CEC), fibroblast (CEF) and high-density mesenchyme 
(HDM) cultures undergoing chondrogenesis in vitro were prepared as described [86, 89]. CEC 
cultures were obtained from sterna of day 14.5 embryos using 0.1 % collagenase treatment. CEF 
cultures were prepared from 8-10 day embryos by trypsin treatment. HDM cultures were made 
from the limb buds of stage 23-24 chicken embryos.  Low-density mesenchyme (LDM) cultures 
were made similarly as HDM cultures, but instead of 5x106 cells, only 1x106 cells were plated in 
35-mm plates in F12/DMEM 1:1 (HyClone Laboratories) supplemented with 10% FBS (Sigma 
and GIBCO Laboratories). COS-7 cells were cultured under standard conditions. HDM cultures 
consisting of early proliferative (stage Ia) chondroblasts and CEC cultures rich in late 
proliferative (stage Ib) chondroblasts represented the low and high Matn1-expressing cell types, 
respectively [16, 17, 87]. LDM, CEF, COS-7 cultures were used as Matn1-nonexpressing 
controls. The C-28I/2 immortalized human costal chondrocyte [90], the SW1353 human 
chondrosarcoma (ATCC HTB-94) and the RCS (rat chondrosarcoma) [91] cell lines were 
cultured in DMEM supplemented with 10% FCS (GIBCO).   
 
4.2. Quantitative real-time PCR (QRT-PCR) 
Total RNA was isolated from CEC, CEF or HDM cultures at subsequent days of 
chondrogenesis using the RNA isolation kit (Macherey-Nagel) according to the manufacturer’s 
instructions. The quantity of isolated RNA was measured by spectrophotometry (NanoDrop). 
QRT-PCR was performed on a RotorGene 3000 instrument (Corbett Research) with gene-
specific primers (Suppl. Table S1) and SybrGreen protocol to monitor gene expression changes. 
The primers were designed by the Roche online primers design tool (https://www.roche-applied-
science.com/sis/rtpcr/upl). Briefly, 2 μg of DNase-treated total RNA from each sample was 
reverse transcribed using the High-Capacity cDNA Archive Kit (Applied Biosystems) according 
to the manufacturer’s instructions. Reactions were done with FastStart SYBR Green Master mix 
(Roche Applied Science) at a final primer concentration of 250 nM as follows: 15 min at 95 oC, 
45 cycles of 95 oC for 15 s, 60 oC for 25 s and 72 oC for 25 s. The quality of the reaction was 
checked by melting temperature analysis after each reaction. The quality of primers was verified 
by MS analysis provided by Bioneer (Daejeon). Each individual Cτ values were normalized to 
the average Cτ values of three internal control genes (GAPDH, 18S rRNA, and 28S rRNA). The 
final relative gene expression ratios were calculated as either 2−ΔCτ values (compared to the 
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internal control genes) or 2−ΔΔCτ values (comparison of the normalized ratios) as indicated in the 
figure legend. 
 
4.3. Plasmid constructions  
All positions are given in bp from the first T of the chicken Matn1 TATA motif. Luciferase 
reporters FO15Luc and AC8Luc driven by the short and long Matn1 promoters, respectively, as 
well as ∆Pe1M1- AC8Luc and ∆Pe1M4- AC85Luc carrying point mutations in the Sox motif and 
spacer of Pe1, respectively, were described [86, 89]. To produce 8xECol2a1-FO15Luc, eight copies 
of ECol2a1 were ligated to the SmaI site of FO15Luc. AC8Luc derivatives ∆IneM1-, ∆IneM2-, 
∆IneM3- and ∆SI2dm-AC8Luc were made by the PCR-based QuickChangeTM Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions using AC8Luc as 
template and oligonucleotides IneM1, IneM2, IneM3 and P1-2d carrying mutation in the Nfi-
binding site of SI [87-89], respectively. Double mutants ∆Pe1M1-∆IneM2-, ∆Pe1M1-∆SI2dm- 
and ∆Pe1M4-∆SI2dm- AC8Luc were constructed similarly using ∆Pe1M1- and ∆Pe1M4-
FO15Luc DNAs as templates. ∆Dpe1ABC- and ∆Dpe1BC- were made by deleting sequences 
between positions −1879/−1791 and −1848/−1791, respectively, from the long Matn1 promoter. 
Mutant derivatives of 8xECol2a1-FO15Luc were made by replacing the wild-type short promoter 
of 8xECol2a1-FO15Luc with the corresponding mutant FO15Luc fragment. Structures and 
sequences of all constructs were verified. Luciferase reporters harboring multiple copies of the 
Dpe1 element upstream of the Matn1 short promoter were made by inserting four copies of the 
PCR-amplified Dpe1 fragment into FO15Luc [88]. 4×Dpe1(−)FO15Luc was generated by 
inserting blunted four copies of Dpe1 into FO15Luc in reverse orientation [92]. PCLuc and 
4×Dpe1(+)PCLuc were generated by replacing the Matn1 short promoter of FO15Luc and 
4×Dpe1(+)FO15Luc, respectively, with the Col2a1 short promoter fragment between positions 
−309/+118. Structures and sequences of all constructs were verified by restriction mapping and 
sequencing. 
 
4.4. Transient expression assays  
CEC and CEF cultures were transfected with 2 µg reporters, while HDM, LDM, and COS-7 
cultures were transfected with 5 µg reporters using the Ca-phosphate coprecipitation method as 
described previously [86, 88, 89]. Cotransfection with pRL-TK (Promega) served as an internal 
control to correct for transfection efficiency, but parallel plates were also transfected with 
FO15Luc. Firefly and renilla luciferase activities were measured in a Luminoscan Ascent 
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(ThermoLabsystem 2.6) using the respective Luciferase Assay Systems (Promega) according to 
the supplier’s instructions 72 h (HDM and LDM) or 48 h (other cells) posttransfection. Relative 
luciferase activities were expressed in fold as compared to values of FO15Luc taken as 1, unless 
noted otherwise. 
Cotransfection assays were performed with 2 µg or 5 µg AC8Luc reporter using effector 
plasmids pcDNA5’UT-FLAG-L-Sox5 (pFSox5), pcDNA5’UT-FLAG-Sox6 (pFSox6), and 
pCDMA-SOX9 (pSOX9) or pcDNA5’UT-FLAG-SOX9 (pFSOX9) [52], plasmids expressing 
Nfi factors and pHmgb1 expressing rat Hmgb1 [93]. In a typical experiment, 125 ng pFSox5, 125 
ng pFSox6 and 250 ng pSOX9 or 250 ng pFSOX9 were added with or without 100 ng pHmgb1. 
Some experiments were performed with increasing amounts of pFSox5 and pFSox6 (0-250 ng) 
or pHmgb1 (0-500 ng). Other experiments were performed with 0 to 300 ng effector plasmids 
expressing mouse Nfia, Nfib, Nfic, and Nfix (pNfia, pNfib, pNfic and pNfix), homologous to 
chicken Nfia1.1, Nfib2, Nfic2, and human NFIX2, respectively [63]. All transfections were done 
in duplicates or triplicates and repeated 3-10 times with at least two different DNA preparations. 
Results are presented as means ± standard error of the mean (SEM). 
Statistical analysis was carried out using one-way analysis of variance (ANOVA) and 
Dunett’s test with KyPlot version 2.0 beta 15. *p<0.05, **p<0.01, ***p<0.001 vs. reporters 
cotransfected with empty vector(s) or mutants vs. similarly cotransfected AC8Luc; #p<0.05, 
##p<0.01, ###p<0.001 as indicated. 
 
4.5. Electrophoretic mobility shift assasy (EMSA) 
Nucleotide sequences of Ine and Pe1 described previously [88], and that of Dpe1 is presented 
later in Fig. 5A. Double-stranded oligonucleotides were synthesized for the Dpe1 element 
comprising positions −1879/−1791: 5'-GAG TCC AGT GTT TTC GTT TTT GGA GGC CCG 
GGG AA-3’ (Dpe1A), 5'-GGA AAA ATT ATG TTT CAT ATA TTA AAA ATA AAC A-3’ 
(Dpe1B), 5'-AAA TAA ACA CTA CTT TTA CAG AGG TAT AAA TGC-3’ (Dpe1C). Coding 
region of Hmgb1 was inserted in frame into pGEX expression vector. GST-tagged L-Sox5, 
SOX9 and Hmgb1 were expressed and purified, and crude cell extracts were made as described 
[88]. 20-30 fmol end-labeled DNA probes were incubated either with 0.6-3.2 μg purified GST-
fused Hmgb1, SOX9, L-Sox5 or 3 μg crude CEC or CEF cell extracts in the presence of 100-500 
ng poly(dG-dC)·(dG-dC) and separated on pre-run 5% or 6.6% PAGE.  
 
4.6. Immunofluorescence 
Acetone-fixed 10-µm cryosections were used for immunofluorescence. Nonspecific binding 
 19
of the antibodies was blocked with 10% normal goat serum. The specimens were incubated at 
4oC overnight with the following primary antibodies in combinations: rabbit affinity purified 
antisera specific for Matn1 [94, 95] (1:200 dilution) and SOX9 (Abcam, ab3697, 1:50) and 
mouse monoclonal antibody for HMGB1 (MBL, M137-3, 1:200). The appropriate secondary 
antibodies were applied at room temperature for 1 h in the dark: Alexa 488-labeled anti-rabbit 
IgG antiserum (Molecular Probes, 1:400), Cy3-conjugated anti-mouse IgG antibodies (Jackson 
Immunoresearch, 1:400). Nuclei were stained with 1 µg/ml Hoechst in PBS for 5 min. The 
specimens were mounted with fluorescent mounting medium (Dako), viewed with a Nikon 
Eclipse E600 microscope equipped with epifluorescence and Pan flour objectives, and 
photographed with Nikon digital camera D5000. After immunofluorescence, the coverslips were 
removed and the sections were restained with hematoxylin and eosin. The images were processed 
using SPOT software (version 4.0.9 for Windows; Diagnostic Instruments) and figures were 
made with Adobe Photoshop 8.0 and CorelDraw X4 softwares. 
 
4.7. Forced expression assays combined with Western analysis and QRT-PCR 
To estimate the relative expression levels of Sox and Nfi proteins, we used pcDNA5’UT-
FLAG-SOX9 (pFSOX9) [52] and we made pFNfib by inserting the NotI (blunted)-NheI 
fragment of Nfi expression plasmids [63] into the EcoRI (blunted)-XbaI sites of pcDNA5’UT-
FLAG. COS-7 cells were cotransfected as described above with AC8Luc, 1 µg pFSOX9 and 
increasing amounts of pFSox5 and pFSox6. In other experiments increasing amounts of pFNfib, 
effector plasmid was used with 1 µg pFSOX9. In addition, we made effector plasmid pFHmgb1 
by inserting the Hmgb1 coding region [93] into pcDNA5’-UT-2FLAG. To estimate the relative 
expression levels of Sox and Hmgb1 proteins, we cotransfected COS-7 cells with 10 µg AC8Luc, 
1 µg each of pFSOX9, pFSox5 and pFSox6, and increasing amounts of pFHmgb1. The 
transfected cells were lysed in 100 µl buffer containing 14 mM HEPES (pH 7.9), 1.5 mM MgCl2, 
6 mM KCl, 0.44 mM NaCl, 0.08 mM EDTA, 3.5 mM DTT, 0.5 mM PMSF, 10% glycerol and 
protease inhibitor cocktail (Sigma-Aldrich P2714). 
To test the induction of the endogenous Matn1 in forced expression assays, we cotransfected 
COS-7 cells with 50 ng pFSOX9, 75 ng pFSox5, and 75 ng pFSox6 without and with 800 ng 
pFHmgb1 using  2µl TurboFect (ThermoScientific, R0531). Transfection mixtures were adjusted 
with empty vectors to the same amount of total DNA. Transfections were made in duplicates and 
repeated 3 times. RNA was isolated from the cells and the Matn1 mRNA level was determined 
by QRT-PCR using the SybrGreen protocol and gene-specific primer pairs (Suppl. Table S2). Cτ 
values were normalized to that of Gapdh. Data are presented as mean ± SEM.  
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4.8. Hmgb1 silencing 
Silencing experiments were performed in chondrogenic cell lines C-28/I2, SW1353, and RCS 
with siRNAs purchased from Bioneer Corporation (Daejeon, Republic of Korea) for human 
HMGB1: 5’-caggaggaauacugaacau-3’; for rat Hmgb1: 5’-cugucaacuucucagaguu-3’; for human 
GAPDH: 5’-gugugaaccaugagaagua-3’, and for negative control siRNA: 5’-
ccuacgccaccaauuucgu-3’. 1.2-2.0 x 105 cells were plated in 6-well plates and transfected with 
100-400 pmoles of siRNA duplexes 24 h after plating using X-tremeGENE siRNA Transfection 
Reagent (Roche Applied Science) as suggested by the supplier. Cultures were harvested 30 h 
(RCS) or 42 h (C-28/I2, SW1353) after transfection. RNA was isolated from the cells and marker 
gene expression levels were determined by QRT-PCR using the SybrGreen protocol and gene-
specific primer pairs (Suppl. Table S2). Gene expression levels were normalized to the invariant 





5.1. Accumulation of Nfi and Sox mRNAs during in vitro chondrogenesis  
To address the potential contribution of Sox and Nfi factors and Hmgb1, we compared the 
kinetic changes in the expression of Matn1, Sox trio, Nfi and other marker genes in various 
chicken primary cultures by QRT-PCR during in vitro chondrogenesis in HDM culture (Fig. 4). 
This culture faithfully mimics the early steps of chondrogenesis as it differentiates to early 
proliferative chondroblasts characterized by elevated Col6a1 expression (Fig. 4A). CEC culture, 
expressing the genes for Sox trio and cartilage proteins at high levels (Fig. 4A-C), represented a 
later stage. CEF culture served as a negative control. In CEF, the steady state mRNA levels for 
Matn1 and the Sox trio were very low, while those for Hmgb1 and Nfi except Nfic were elevated 
relative to their levels in committed mesenchyme (HDM day 0) (Fig. 4B-E). 
 
 
Fig. 4. Comparison of the marker gene expression by QRT-PCR during in vitro chondrogenesis. (A-
E) Marker mRNA levels were determined by QRT-PCR in HDM culture undergoing chondrogenesis in 
vitro and compared to mRNA levels of non-expressing CEF and high Matn1-expressing CEC cultures. Cτ 
values were normalized to the average Cτ values of three internal control genes. Relative expression levels 
are presented as fold values relative to the HDM day 0 values. 
 
Unlike the slow continuous accumulation of Col2a1 mRNA during early stages of 
differentiation in HDM culture, activation of Matn1 was first detected in HDM culture at day 4 
(Fig. 4A and B). Sox9 and Col2a1 mRNAs accumulated with similar kinetics, but the low levels 
of L-Sox5 and Sox6 mRNAs increased sharply only in CEC culture, except for a small, transient 
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boost of Sox6 mRNA at days 3 and 4 in HDM culture, just preceding the first peak in the Matn1 
mRNA level (Fig. 4B and C). Interestingly, Matn3 and Matn4, although also expressed in 
cartilage, exhibited smaller increase in their relative expression level than Matn1 (Suppl. Table 
S1). Matn4 level, however, peaked in HDM culture suggesting a function in early stage of 
chondrogenesis (Fig. 4B). Remarkably, from a very low expression level compared to the 
internal control genes measured in committed mesenchyme (Suppl. Table S1), Matn1 expression 
showed the highest relative increase (2057-fold) in CEC culture, in contrast to the lower increase 
in the level of Col2a1 (181-fold) and other cartilage ECM genes (<80-fold, compared to HDM 
day 0) (Fig. 4A and B). The relative Nfi mRNA levels also increased transiently 2.6 to 22-fold 
with two peaks at day 4 and days 6-7 in HDM culture, followed by a sharp decline in CEC 
culture close to 1 (Nfia and Nfix) or below 1 (Nfib and Nfic) (Fig. 4D). In contrast, Hmgb1 
mRNA level declined gradually in HDM culture, exhibiting the lowest level in CEC culture (Fig. 
4E). Thus, CEC culture, rich in late proliferative chondroblasts, is characterized by high Matn1 
and Sox trio, but low Nfi and Hmgb1 mRNA levels. Day 4 HDM culture, consisting of early 
proliferative chondroblasts, however, exhibits high Nfi, but lower Matn1, Sox9 and Sox6 mRNA 
levels and very low L-Sox5 mRNA expression. Sox6 and Nfi mRNA levels peaked in HDM 
culture at the time of Matn1 activation, suggesting a function in Matn1 regulation. 
 
5.2. Comparative binding of Sox transcription factors to the conserved Matn1 promoter 
elements in vitro 
It was reported previously that evolutionarily conserved Matn1 DNA elements feature 
putative Sox motifs (Fig. 3) [86] and Pe1 and Ine were demonstrated to interact with SOX9 in 
vitro [86, 88, 89]. Therefore, we hypothesized that Sox factor-mediated interactions may play 
important role in the chondroblast developmental stage-dependent regulation of Matn1. To test 
this hypothesis, first we compared the binding of purified chondrogenic Sox factors to Dpe1 and 
the short promoter elements Pe1 and Ine (Fig. 5).  
We found that the chicken Dpe1 element harbors three putative sites with tandem and 
inverted paired motifs, which share 5/7 or 6/7 nucleotide identity with the Sox consensus 
sequence (Fig. 5A). These motifs also show 5/10 to 8/10 nucleotide identity with 
AGAACAATGG, the preferred Sox9-binding site [96]. We performed EMSA experiments to 
demonstrate that the element carries at least three sites which can interact with purified Sox 
proteins in vitro. Each of the three subfragments of Dpe1 was clearly recognized by GST-fused 
SOX9 and L-Sox5, but with inverse binding efficiency (Fig. 5B and C). SOX9 exhibited the 
strongest binding to Dpe1C forming two complexes and weaker binding to Dpe1A and Dpe1B 
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forming one and three diffuse complexes, respectively (Fig. 5B). On the other hand, L-Sox5 most 
preferably recognized Dpe1B, followed by A and C (Fig. 5C). We found that SOX9 bound the 
Matn1 control elements with highly variable efficiency. Whereas it showed more potent complex 
formation in vitro with each of the Dpe1 Sox sites, than with those of Ine, SOX9 bound Pe1 even 




Fig. 5. Comparison of binding purified GST-fused Sox proteins to the conserved DNA elements. (A) 
Nucleotide sequences of Dpe1, Pe1 and Ine elements. Large arrows mark the subfragments of Dpe1 and 
small arrows depict the Sox motifs of the elements. The conserved GTGCC motif the 5’ (I) and 3’ (II) 
paired Sox sites and unrelated factor-binding site (III) of Ine are denoted. Comparison of binding of GST-
fused SOX9 (B) and L-Sox5 (C) to the Dpe1 subfragments, Ine and Pe1 in EMSA. F, free probe. 
 
 
Pe1, the most conserved DNA element in amniotes bears a palindrome very similar to the 
preferred Sox9-binding site (Fig. 3B) [86, 96]. This motif was recognized by the Sox trio in vitro 
and protected in genomic footprinting in our laboratory [86]. Consistent with these previous 
findings, we observed that as opposed to purified L-Sox5, SOX9 binds most efficiently Pe1 
among the conserved Matn1 elements (Fig. 4B and C), strongly suggesting that Pe1 likely plays a 
key role in Sox-mediated interactions. Conserved sequences with two pairs of inverted Sox 
motifs were also found in the Ine element of mammals and the sequence was less conserved 
between mammals and chicken, but the chicken sequence also featured two paired Sox motifs 
around the transcription start site (Fig. 3A) and [97]. A conserved GTGCC motif in Ine, and an 
Nfi site upstream of TATA were also found. In agreement with other observations in our 
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laboratory [88], Ine interacted with SOX9 and L-Sox5 with low efficiency (Fig. 5B and C). 
SOX9 and L-Sox5 bound somewhat more strongly to the 5’ and 3’ Sox-binding sites, 
respectively. In fact, purified Sox factors bound the 5’ and 3’ Sox sites of Ine cooperatively in 
EMSA [88].  
Interaction of Dpe1 with SOX9 and L-Sox5 in vitro supports the hypothesis that it may exert 
enhancement via binding Sox factors. The strongest interaction of Pe1 with SOX9 suggests that 
element plays a crucial role in SOX9-mediated transactivation from the upstream elements. The 
L-Sox5/Sox6 bound to Ine may modulate transactivation by SOX9. Interaction of Ine with Sox 
factors was the weakest among the elements.  
 
5.3. The Pe1 Sox site and SI Nfi site are indispensable for promoter activation in 
transiently transfected chondrocytes  
To study the contribution of conserved DNA elements to promoter activity, we introduced 
point mutations into Ine, Pe1, and Dpe1 and measured their effect on the activity of long 
promoter constructs (AC8Luc) (Fig. 6A and B). As the SI element is also conserved in the short 
Matn1 promoter of amniotes (Fig. 3A) [97] and it is recognized by Nfi proteins in vitro and in 
vivo [86, 89], we similarly studied that effect of SI mutation on the long promoter activity. The 
−2011/−334 sequence enhanced the short promoter activity ~19-fold in AC8Luc in CECs, but 
hardly did so in low- or non-expressing cultures (Fig. 6A). Sox site mutations IneM1, IneM2 and 
IneM3 (Fig. 6B) cut the long promoter activity to half or more in CECs. The effect of Pe1M4, 
which carried a mutation unrelated to Sox binding site [86], was similar, but Pe1M1, in which the 
Sox site of Pe1 was disrupted, dropped the long promoter activity 13-fold, abolishing CEC-
specific enhancement from upstream elements (Fig. 6A). The double mutant Pe1M1/IneM2 
disrupting all the three Sox- binding sites in the short promoter decreased the long promoter 
activity (p<0.05) even closer to that of FO15Luc. Thus, the Sox sites in Pe1 and Ine are needed to 
mediate promoter activation from upstream elements. Deletion of the entire Dpe1 element or its 
subfragments B and C decreased the long promoter activity by 4-fold and 2-fold, respectively, in 
CEC culture, while deletion of Dpe2 had milder effect (data not shown).  
Considering that the SI element was protected in genomic footprinting in CEC culture [86, 
89] and bound Nfi proteins in vitro [87], we also mutated its Nfi contact points. Mutation SI2dm 
either alone or in combination with Pe1M1 or Pe1M4 dropped the long promoter activity by 10-
fold in CEC and similarly in other cultures indicating tissue-unspecific inhibition (Fig. 6A). 
Double mutation Pe1M1/SI2dm further diminished the activity (p<0.001) to the basal promoter 
level in mesenchymal cells suggesting an additive or synergistic effect. Thus, disruption of the 
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Fig. 6. Effect of Ine, Pe1 and SI mutations and Dpe1 deletion on the long promoter activity in 
mesenchymal cultures. Transient expression activities of wild-type and mutant versions of reporters 
AC8Luc (A) and 8xECol2a1-FO15Luc (C) driven by long Matn1 promoter or multiple ECol2a1 fused to the 
short promoter, respectively. Schematic to the left indicate single or double mutations introduced into the 
promoter (B) Sequences of wild-type or mutant version of DNA elements. Sox- and Nfi-binding sites are 
indicated (A and C). Luciferase activities of wild-type (wt) and mutant reporters in the low-, high-, and 
nonexpressing HDM, CEC, and CEF cultures, respectively, are presented in fold relative to that of 




We concluded that albeit Ine recognition by Sox factors may be involved, Sox factor binding 
to Pe1 seems to be more crucial for promoter activation in CEC culture rich in late proliferative 
chondroblasts. However, the short promoter elements alone direct only a low reporter gene 
activity and promoter upstream elements are needed for its enhancement. We found that Dpe1 is 
a very important upstream element necessary for the activation of the short promoter. These data 
are consistent with the high enhancement of the short promoter by multiple copies of Dpe1 in 
CEC culture and transgenic mice [88]. In addition, binding of the ubiquitous Nfi to SI near the 
TATA box may be similarly crucial. The position-specific conservation of motifs similar to the 
NFI consensus [98] near TATA in amniotes [88] further supports the importance of SI in the 
regulation of the gene. The significant, but less dramatic effect of other mutations suggests that 
binding of factors to the Pe1 spacer and to the conserved motif of Ine may also be needed for full 
promoter activity. 
 
5.4. Sox and Nfi sites of the short promoter are important for enhancement by a 
heterologous cartilage-specific enhancer.  
Next we tested the activation of the short promoter by a heterologous cartilage enhancer. 
Toward this end we chose multiple copies of the Col2a1 enhancer element (ECol2a1), which is 
known to function in chondrocytes independent of their differentiation stages [78]. Eight copies 
of ECol2a1 robustly increased the short promoter activity in CEC, but had no effect in CEF or in 
HDM cultures consisting of early proliferative chondroblasts (Fig. 6C). Lining up with transgenic 
mouse data [88], these results indicate that the Matn1 short promoter also restricted the broad 
cartilage-specific enhancement by ECol2a1 to late proliferative chondroblasts in tissue culture.  
Mutations Pe1M1, IneM2, SI2dm and Pe1M1/IneM2 decreased the relative activity of 
8xECol2a1-FO15Luc by 43.6%, 46.6%, 64.9%, and 78%, respectively, in CEC culture (Fig. 6C). 
Thus, our data show that whereas Sox factor binding to Pe1 is crucial for the interaction between 
the homologous distal and proximal DNA elements, Sox9 binding to Pe1 and Ine is less essential 
for mediating enhancement from ECol2a1. Disrupting all Sox sites of Pe1 and Ine or the Nfi site of 
SI, however, highly diminished the enhancement, supporting the hypothesis that the short 
promoter elements may also interact with the heterologous enhancer via the bound Sox and Nfi 
factors.  
 
5.5. Dose-dependent synergy of L-Sox5/Sox6 with SOX9 
Next we assessed the activation of the Matn1 long promoter by cotransfected Sox proteins 
(Fig. 7A-D). While SOX9 doubled it, L-Sox5/Sox6 decreased the promoter activity to about half 
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Fig. 7. Dose-dependent activation of the Matn1 promoter and Dpe1 fused to homologous or 
heterologous short promoters by the Sox trio. (A-D) AC8Luc was cotransfected with Sox expression 
plasmids in various mesenchymal cultures as indicated (A-B) and COS-7 cells (C-D). Combined forced 
expression assay and Western analysis with anti-FLAG antibody (C). Forced expression assays were 
performed with constant amount of FLAG-tagged expression plasmid for SOX9 and increasing amount of 
expression plasmids for L-Sox5 and Sox6. (E) Map of the reporters driven by four copies of Dpe1 fused 
to the homologous Matn1 or the heterologous Col2a1 short promoters in direct or reverse orientations as 
indicated. (F-G) Dose-dependent synergistic activation of these reporters by forced expression of the Sox 
trio. Luciferase activities are presented as fold values relative to that for AC8Luc (A-D), FO15Luc (F) and 
PCLuc (G). *p<0.05, **p<0.01, ***p<0.001 compared with reporter cotransfected with vectors (A-D) or 
vs. vector-cotransfected 4xDpe1-reporters (F-G); #p<0.05, ##p<0.01, ###p<0.001 compared with SOX9 
cotransfected reporters (A-D) or as indicated (C,F and G). 
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in mesenchymal cells (Fig. 7A). Coexpression of L-Sox5/Sox6 with SOX9 greatly or moderately 
increased the ability of SOX9 to activate the promoter in CEF and HDM cultures, respectively, 
but rather decreased it in CEC culture. This indicates synergy between Sox proteins at early 
differentiation stages. When we introduced constant amount of pSOX9 and increasing amounts 
of pSox5 and pSox6 expession plasmids into CEF, LDM and HDM cultures, the synergistic 
activation peaked at low ratio of pSox5 and pSox6 versus pSOX9, and declined at elevated ratio 
to the level achieved by SOX9 alone (Fig. 7B). Highest activation was seen in CEF (3.5-fold), 
followed by that in LDM and HDM cultures in inverse correlation with the endogenous Sox5 and 
Sox6 expression levels of these cultures (Fig. 4C), raising the possibility that L-Sox5/Sox6 may 
modulate the activation by SOX9 in a dose-dependent manner.  
We confirmed this hypothesis by forced expression of FLAG-tagged Sox trio in 
nonchondrocytic COS-7 cells and monitoring the protein expression in Western blots (Fig. 7C). 
Despite the low effect of SOX9 alone, L-Sox5/Sox6 synergized with SOX9 to activate the long 
promoter up to ~18-20-fold at low molar excess. The activation was high from 0.9:1 to 3.6:1 
molar ratio of L-Sox5/Sox6 to SOX9 in repeated experiments, but the synergy dropped above 
5.3:1 molar ratio (Fig. 7C). L-Sox5 and Sox6 had similar effect with sharper decline for Sox6 
(Fig. 7D).  
We concluded that L-Sox5/Sox6 can finely tune the Matn1 promoter by greatly increasing 
the ability of SOX9 to activate the promoter at low molar excess to SOX9 (early stages of 
chondrogenesis), or decreasing the activation by SOX9 at high excess (late stage), possibly by 
competing with SOX9 for its binding sites.  
 
5.6. Dpe1 can function as a cartilage-specific enhancer element in cotransfection 
experiments in culture 
Next we assessed, if Dpe1 elements can exert Sox trio-mediated enhancement to homologous 
and heterologous promoters in COS-7 cells forced to express constant amount of SOX9 and 
increasing amounts of L-Sox5 and Sox6 (Fig. 7E-G). Four copies of Dpe1 increased the activity 
of the Matn1 and the Col2a1 promoters by 3.1- and 6-fold, respectively, which was not or only 
slightly increased further by forced expression of SOX9 or L-Sox5/Sox6 alone (Fig. 7F and G). 
L-Sox5/Sox6, however, synergized with SOX9 in a dose-dependent manner to mediate a 17- and 
23-fold activation of the Matn1 and Col2a1 short promoters, respectively, from the Dpe1 
elements. As the Dpe1 elements worked efficiently in both orientations (Fig. 7F) and enhanced 
even the heterologous Col2a1 promoter (Fig. 7G), we concluded that Dpe1 can function as a 
cartilage-specific enhancer element. 
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5.7. Pe1 mutation and Dpe1 deletion hampers the transactivation by SOX9, Ine mutants 
decrease the synergism with L-Sox5/Sox6 
Next we studied the effect of Pe1, Ine and SI mutations and Dpe1 deletion on the SOX9- and 
Sox trio-mediated enhancement in coexpression assays (Fig. 8A). In COS-7 cells forced to 
express L-Sox5/Sox6 in optimal abundance to SOX9, Pe1M1/IneM2 decreased the synergistic 
activation of the long promoter by 96.1%, followed by SI2dm and Pe1M1 (85.5-89%) (Fig. 8A 
and B). Pe1M1/IneM2 and SI2dm also repressed the SOX9-mediated activation by ~70%. 
Pe1M1/IneM2 similarly decreased the SOX9 and/or Sox trio mediated activation by 70-96%, 
when L-Sox5/Sox6 was coexpressed in higher excess to SOX9 in LDM, and CEC cultures (Fig. 
8C and D). Thus disruption of all the three Sox sites of the short promoter abolished the 
transactivation by SOX9 and the Sox trio even in the presence of intact upstream elements. The 
effect of Pe1M1 was only somewhat milder, demonstrating that SOX9 binding to Pe1 is critical 
for the SOX9-mediated promoter activation at both early and late stage of chondrogenesis.  
Ine mutations diminished the synergistic activation of SOX9 by optimal excess of L-
Sox5/Sox6 in COS-7 cells (Fig. 8A and B). In LDM culture, IneM1 and IneM3 also abolished 
the activation of AC8Luc by SOX9, whereas IneM3 and IneM2 more drastically diminished the 
synergistic effect of elevated L-Sox5/Sox6 than IneM1 (Fig. 8C). In keeping with the effect of 
Ine mutations in EMSA [88], this indicates that even though Sox factors bind both the 5’ and 3’ 
Sox sites of Ine (Fig. 5D-F), the 3’ site equally interacts with SOX9 and L-Sox5/Sox6, but the 5’ 
site is preferably recognized by SOX9 in early proliferative chondroblasts. IneM1 also hampers 
the activation by SOX9 in CEC culture (Fig. 8D). Notably, mutation of the Nfi site of SI also 
abolished or highly decreased the SOX9- and Sox trio-mediated promoter activation in the 
cultures tested (Fig. 8). Variable effect of Pe1M4 mutation and the low effect of SOX9 in COS-7 
cells indicate that ubiquitous and/or Sox partner factors may also bind the promoter elements. 
Deletion of Dpe1 decreased ~3-fold the transactivation of the promoter with SOX9 in LDM 
culture and close to half in CEC culture (Fig. 8C-D). It also decreased to half the synergistic 
activation by the Sox trio in LDM culture or in COS-7 cells forced to express L-Sox5/Sox6 in 
optimal dose relative to SOX9, but not in CEC culture expressing the Sox trio at high level (Fig. 
8). 
We concluded that SOX9 binding to Pe1 plays key role in mediating the enhancement from 
distal elements. L-Sox5/Sox6 expressed in low relative abundance and bound to Ine can 
synergistically increase the activation by Pe1-bound SOX9 at early stage of chondrogenesis. At 
late stage, however, when produced in large excess to SOX9, L-Sox5/Sox6 may decrease the 
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Fig. 8. Effect of point mutations on the synergistic activation of the long promoter by the Sox trio in 
cultures. (A) Schematic indicates factor binding to the short promoter and upstream element (Dpe1). Thin 
and thick arrows depict the transcription efficiency at early (E) and at late stage (L) of chondrogenesis. 
(B-D) Activation of wild-type and mutant reporters by L-Sox5/Sox6 and SOX9 coexpressed at optimal 
(2.7:1) molar ratio in COS-7 cells (B) and at higher ratio in LDM (C) and CEC (D) cultures. Luciferase 
activities are given in fold relative to that of AC8Luc.  *p<0.05, **p<0.01, ***p<0.001 mutants vs. 
similarly cotrasfacted AC8Luc (B-D); #p<0.05, ##p<0.01, ###p<0.001 as indicated (B-D). 
 
 
activation by SOX9, possibly by competing for its binding sites. In addition, Nfi binding to SI 
and other factor binding to Pe1 and Ine is also needed for efficient promoter activation. Based on 
deletion analysis, SOX9 binding to Dpe1 plays an important role in promoter activation in late 
proliferative chondroblasts, possibly via Sox-mediated interactions with Pe1. In early steps of 
chondrogenesis, however, SOX9 binding to Dpe1 as well as synergistic activation of SOX9 by an 
optimal dose of L-Sox5/Sox6 is also needed for promoter enhancement.  
 
5.8. Nfi proteins modulate the promoter activity  
Next we studied the effect of Nfi on AC8Luc activity in cotransfection assays. In CEC 
culture, all Nfi proteins, except Nfia at low concentration, robustly inhibited the long promoter 
activity (Fig. 9A). When Nfi and SOX9 were expressed at an optimal ratio, Nfib and Nfic 
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Fig. 9. Modulation of the Matn1 promoter activity by cotransfected Nfi proteins. (A-D) AC8Luc was 
cotransfected with increasing amount of Nfi expression plasmids without or with constant amount of 
SOX9 expression plasmids in cultures as indicated. (D) Combined forced expression and Western analysis 
in COS-7 cells. Flag-tagged SOX9 and Nfi proteins were detected by Western analysis using anti-FLAG 




decreased significantly the transactivation by SOX9, but all Nfi proteins exerted 74% to 90% 
repression at higher ratio (Fig. 9B). In COS-7 cells, Nfia and Nfib in optimal amount indeed 
cooperated with SOX9 and potentiated its transactivation of the long promoter (Fig. 9C). The 
activation, however, declined at higher levels of Nfia and Nfib. In contrast, Nfic and Nfix 
inhibited the activation by SOX9. Forced expression of FLAG-tagged proteins in COS-7 cells 
revealed that the activation increased up to ~2:1 molar ratio of Nfib to SOX9, but significantly 
decreased above ~4:1 molar ratio (Fig. 9D). 
These data suggest that Nfi proteins may increase or decrease SOX9-mediated 
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transactivation of Matn1 depending on their abundance relative to SOX9 (see later Fig. 15A). 
The conservation of Nfi sites near TATA and Pe1 [88] underlines the importance of Nfi proteins 
in the restricted cartilage-specific expression of Matn1 in amniotes. 
To sum up, our data suggest a model of the developmental-stage specific regulation of Matn1 
(see later Fig. 15A). This model involves unique arrangement of conserved DNA elements. Short 
promoter elements Pe1 and Ine bind preferentially to Sox9 and L-Sox5/Sox6, respectively; and 
SI and SII elements are recognized by Nfi proteins. The promoter upstream enhancer element 
Dpe1 interacts with the Sox-trio. Developmental stage-specific regulation is achieved, as binding 
and activity of the Pe1-bound Sox9 is dose-dependently modulated by the Ine-bound L-
Sox5/Sox6 proteins. Dpe1 enhances the promoter activity via Sox-mediated interaction with Pe1. 
 
5.9. Hmgb1 is expressed in early chondrogenesis in inverse correlation with 
chondrogenic markers  
Sox proteins and Hmgb1 have similar HMGB domains and Hmgb1 secreted by hypertrophic 
chondrocytes was implicated in late steps of endochondral ossification [8], but its function in 
early steps has not been studied yet. To address the possible involvement of Hmgb1 in 
chondrogenesis, we used double immunofluorescence to monitor Hmgb1 expression in the 
developing limbs of mouse embryos (Fig. 10). We observed that the ubiquitous Hmgb1 
immunosignal started to decrease in early steps of chondrogenesis, showing overlap with Sox9 in 
condensed mesenchyme, prechondrocytes and early chondroblasts (Fig. 10A, B, and D). In line 
with former data [3, 20, 57], Matn1 had a narrower spatiotemporal expression pattern than Sox9, 
being first detectable only in early chondroblasts with some delay (Fig. 10C and E). Thus only a 
very limited overlap was seen between Hmgb1 and Matn1 in the latter cells at the onset of Matn1 
(Fig. 10E). Hmgb1 expression, however, dropped as chondrogenesis progressed, exhibiting a 
complementary pattern to that of Sox9 (Fig. 10B and D) and Matn1 (Fig. 10C and E) in overtly 
differentiated cartilaginous elements.  
These results are consistent with the kinetic changes in the marker gene expression we 
revealed by QRT-PCR in HDM culture undergoing chondrogenesis in vitro (Fig. 4E). The 
Hmgb1 mRNA level was highest in CEF culture, it declined gradually during differentiation in 
HDM culture and it was the lowest in CEC culture. Down-regulation of Hmgb1 during 
chondrogenesis was more pronounced than that of Hmgn1 known to activate Sox9 [99]. Both 
Hmgb1 and Hmgn1 levels showed an inverse correlation with those of Sox9, Sox5 and most of 
the cartilage ECM genes (Col2a1, Col11a1, Matn1, and Matn3) (Fig. 4A-C and E). At day 4 
when Matn1 was first detected in HDM culture, the sharply declining Hmgb1 mRNA level 
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Fig. 10. Expression of Hmgb1 is complementary to those of Sox9 and Matn1 in the developing mouse 
limb. Double immunofluorescence on consecutive cryosections of E12 (A) and E14.5 mouse embryos (B-
E). Hematoxylin-eosin staining of the same cryosections is shown below for comparison. The expression 
domains of Hmgb1 and Sox9 overlap with each other in early steps of chondrogenesis just before and at 
the time of activation of Matn1. Note the overlapping Hmgb1 and Sox9 signals e.g. in condensed 
mesenchyme or prechondrocytes (asterisk) and early chondroblasts of developing metarsals (arrowhead) 
(A, B and D), which exhibit no or yet low Matn1 immunosignal, respectively (C and E). In the overtly 
differentiated cartilaginous elements, however, the Hmgb1 signal ceases, complementary to the high Sox9 




(1.5x10−3) relative to the internal control genes was only 2.3-fold higher than the increasing Sox9 
mRNA level (6.6x10−4) (Suppl. table S1). This ratio decreased to 1.3 by day 7 in HDM culture. 
In CEC culture consisting mostly of late proliferative (stage Ib) chondroblasts, however, the 
mRNA levels for Sox9 and L-Sox5 were 21.5-fold and 15.5-fold higher, respectively, than that 
for Hmgb1.  
To sum up, Hmgb1 expression gradually declined in an inverse correlation with the activation 
of the chondrogenic Sox and ECM genes during limb development and in chondrogenic cultures, 
exhibiting a small overlap in their expression domains in early steps of in vivo and in vitro 
chondrogenesis. Coexpression of Hmgb1 and Sox9 at comparable levels just before and at the 
time of the onset of Matn1 raises the possibility that, in addition to Sox9, Hmgb1 may also 
contribute to the gene regulation in early steps of chondrogenesis.  
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5.10. Hmgb1 increases the Matn1 promoter activity in cotransfection assays in early 
stages of chondrogenesis 
Next we assessed whether Hmgb1 can influence the Matn1 promoter activity in 
cotransfection assays. We observed transient activation of the long promoter by increasing 
amount of pHmgb1 expression plasmid with the highest peak (2.6-fold) in HDM culture and a 
lower increase in LDM and CEF cultures (Fig. 11A). The small transient increase, however, 
turned to inhibition at higher doses of Hmgb1 in CEC culture. Thus, Hmgb1 can markedly 
increase the long promoter activity in mesenchymal cultures, where the Sox trio expression is 
low and the in vivo occupancy of Sox-binding sites of Pe1 and Ine is very limited [86, 89]. In 
CEC culture, however, where the Sox trio expression is high and Pe1 and Ine are occupied by in 
vivo bound factors [86, 89], elevated amount of Hmgb1 does not activate, but rather inhibits 
transcription. Therefore, we hypothesized that Hmgb1 acting as an architectural protein may 
increase the promoter activity in early steps of chondrogenesis and facilitae the synergistic 
activation by the Sox trio.  
To test this hypothesis, we measured the long promoter activity by coexpressing Sox proteins 
with optimal amount of Hmgb1. In increasing dose, SOX9 gradually increased, whereas L-
Sox5/Sox6 gradually decreased the promoter activity in mesenchymal cultures (data not shown). 
When constant amount of SOX9 and increasing amount of L-Sox5/Sox6 were coexpressed with 
and without optimal amount of Hmgb1, Hmgb1 exerted only a small significant increase in the 
transactivation by SOX9, but it doubled the dose-dependent synergistic activation of SOX9 by L-
Sox5/Sox6 in LDM and HDM cultures, by compensating the decline caused by higher doses of 
L-Sox5/Sox6 relative to SOX9 (Fig. 11B). In CEF culture, Hmgb1 activation (2.1-fold) peaked at 
optimal dose of L-Sox5/Sox6 versus SOX9, thus raising the promoter activity up to 9.3-fold (Fig. 
11B and C).  
To further prove that Hmgb1 can facilitate the synergistic promoter activation by the Sox trio, 
we forced to express constant amount of Sox proteins and increasing amount of Hmgb1 in COS-
7 cells and monitored the expression of the FLAG-tagged proteins in Western blots (Fig. 11D). 
We found that the Sox trio-mediated 17.6-fold enhancement of the promoter activity increased 
further to 38-fold at ~3:1 molar ratio of Hmgb1 to SOX9. 
We concluded that optimal dose of Hmgb1 can facilitate the dose-dependent synergistic 
activation of the Matn1 promoter by the Sox trio in early chondrogenesis or in cultures 
expressing the Sox trio at a low level. The activation, however, turns to inhibition in CEC culture 




Fig. 11. Effect of Hmgb1 on the synergistic activation of Matn1 promoter by the Sox trio. (A) 
Transient activation of the long promoter by Hmgb1 in cotransfection assays. (B- C) Effect of 
coexpressed Hmgb1 and Sox trio on the long promoter activity in mesenchymal cells. (D) Forced 
expression of increasing amount of FLAG-tagged Hmgb1 and constant amount of Sox trio in COS-7 cells 
combined with Western analysis using anti-FLAG antibody. Nonspecific bands are marked with asterisk. 
Luciferase activities are presented as fold values relative to that for AC8Luc (A, B and D) or for Hmgb1-
cotransfected AC8Luc (C). *p<0.05, **p<0.01, ***p<0.001 vs. vector-cotransfected reporter (A-D); 




5.11. Hmgb1 facilitates activation of the endogenous Matn1 in forced expression assays   
Next we performed forced expression experiments in COS-7 cells to test whether optimal 
levels of the chondrogenic Sox proteins are sufficient for ectopic induction of the chromosomal 
Matn1 and whether Hmgb1 can enhance the induction. As shown in Table 1, forced expression 
of the Sox trio in optimal L-Sox5/Sox6 dose relative to Sox9 increased the very low expression 
level of the endogenous Matn1 by 26-fold. Forced expression of Hmgb1 did not have a 
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significant effect alone, but together with the Sox trio it increased the Matn1 expression level by 
79-fold as compared to the vector-transfected control. This confirms the ectopic induction of the 
endogenous Matn1 by forced expression of Sox trio in the nonexpressing COS-7 cells and an 
additional 3-fold activation by forced expression of Hmgb1. We concluded that Hmgb1 can 
facilitate not only the Sox trio-mediated activation of the reporter gene driven by the long Matn1 




Table 1. Induction of the endogenous Matn1 in the nonexpressing COS-7 cells by 
forced expression of the Sox trio and Hmgb1 
Transcription factors  Matn1 expression level       
expressed by force        2-ΔCτ±SEMa   fold      p value 
Empty Vector  1.95E−06 ± 1.47E−07      1        
Hmgb1   2.42E−06 ± 2.87E−07    1.24     9.90E−01 
Sox trio   5.03E−05 ± 5.64E−06  25.76     7.08E−03 
Sox trio + Hmgb1 1.54E−04 ± 2.65E−05  78.68     2.25E−05 
aMatn1 mRNA levels are given relative to the invariant Gapdh mRNA level. 
 
 
5.12. Hmgb1 forms nucleoprotein complexes on the Matn1 promoter elements in vitro 
We next studied the in vitro interaction of the conserved DNA elements with GST-fused purified 
Hmgb1. In inverse correlation with their SOX9-binding efficiency, Dpe1A and Dpe1B bound 
more strongly whereas Pe1 and Dpe1C bound weakly to Hmgb1 (Fig. 12A). Ine showed weak 
interaction with both proteins. When Hmgb1 was added in increasing amount together with Sox 
factors, it modulated the binding of Sox factors to the elements in a dose-dependent manner (Fig. 
12B and C). Curiously, it decreased the binding of SOX9 and L-Sox5 to Dpe1A or, after an 
inhibition at a low dose, it transiently increased the formation of L-Sox5 and SOX9 complexes 
on Dpe1B at higher doses of Hmgb1 relative to Sox factors. In contrast, Hmgb1 increased the 
binding of Dpe1C, Ine and Pe1 to SOX9 and L-Sox5 at an optimal dose, followed by a decrease 
at higher dose. Hmgb1 also modulated the binding efficiency of SOX9 in the presence of L-
Sox5: either decreased both (Ine) or dose-dependently increased the formation of SOX9-specific 
complexes (Pe1 and Dpe1C) or transiently increased the formation of L-Sox5 complexes, while 
transiently inhibited the SOX9 complexes (Dpe1A and Dpe1B). Pe1M1 mutation disrupting the 
paired Sox9 motifs, but not the palindrome structure of Pe1, extremely reduced SOX9 binding to 
the element, but it did not alter the weak recognition by Hmgb1 (compare Figs. 5B, 12A and D). 
Hmgb1 somewhat increased SOX9 binding to Pe1M1, while it decreased L-Sox5 binding.  
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Fig. 12. Hmgb1 binds to conserved Matn1 control elements in vitro. (A) Purified GST-fused Hmgb1 
binds the DNA elements with variable efficiency in EMSA. Binding of purified SOX9 and L-Sox5 to 
Dpe1 (B) and short promoter elements Ine and Pe1 (C) in the presence of increasing amount of purified 
Hmgb1. (D) Hmgb1 binds with similar efficiency to Pe1 and Pe1M1 harboring palindrome sequences. F, 
free probe; H, Hmgb1 complex; S5, L-Sox5 complex; S9, SOX9 complex. 
 
 
These data show that Hmgb1 can interact with Matn1 control elements Dpe1, Pe1 and Ine in 
vitro and it can modify the binding of Sox proteins. 
 
5.13. Compensatory effect of Hmgb1 on proximal promoter mutations 
Next we tested how point mutations in the Sox or other sites of Pe1 and Ine [88] affected the 
Hmgb1-facilitated activation of the Matn1 long promoter by the Sox trio (Fig. 13). As opposed to 
the lack of any significant effect in CEC culture (Fig. 13C), Hmgb1 increased the Sox trio-
mediated synergistic activation of the wild-type promoter and some of its mutants in LDM 
culture (Fig. 13B).  
Thus, it doubled the activity of derivatives ΔPe1M1 or ΔIneM1, carrying mutations in the 
Sox site of Pe1 or the 5’ Sox site of Ine, respectively. It also elevated the activity of ΔPe1M4 
lacking factor binding to the Sox spacer. In contrast, mutation IneM2, disrupting both Sox sites 
and an unknown factor binding site of Ine, obstructed the positive effect of Hmgb1, decreasing 
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Fig. 13. Effect of Hmgb1 on the Sox trio-mediated transactivation of the long promoter and its 
mutant derivatives. (A) The schematic (not drawn to scale) illustrates factor binding to the short 
promoter and upstream elements. Arrows indicate transcriptional activities at early stage of 
chondrogenesis (E). Sox proteins were coexpressed with and without Hmgb1 in LDM (B) and CEC 
cultures (C) and reporter activities were expressed in fold values relative to that for AC8Luc cotransfected 
with vectors. *p<0.05, **p<0.01, ***p<0.001 mutants vs. similarly cotransfected AC8Luc; #p<0.05, 
##p<0.01, ###p<0.001 as indicated.  
 
 
the activity to half. In spite of the significant, but small activation by Hmgb1, deletion of 
Dpe1ABC or mutation in the 3’ Sox site of Ine (IneM3) or the double mutant Pe1M1/IneM2 
decreased the transactivation by 60-76%.  
Thus in early stage of chondrogenesis, Hmgb1 can partly or fully compensate for the lack of 
factor binding to the Sox site of Pe1 and its spacer or to the 5’ Sox site of Ine. However, it could 
not compensate for the lack of factor binding to the 3’ or both Sox sites of Ine or to Dpe1. 
Pe1M1, Pe1M4, and IneM1 did not destroy the palindrome structure of Pe1 and Ine, whereas 
IneM3 and IneM2 disrupted one or both palindromes of Ine, respectively (Fig. 5A) [88, 89]. 
Dpe1 also harbors palindrome sequences (Fig. 5). This suggests that Hmgb1 facilitated the Sox 
trio-mediated activation of the promoter and some promoter mutants not disrupting the 
palindrome structures of the elements. One explanation can be that Hmgb1 may bind to such 
palindrome sequences and by prebending the DNA, it may facilitate the binding of Sox and 
partner factors to the Matn1 control elements in early chondrogenesis, thereby compensating for 
the negative effect of point mutations. 
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5.14. Effect of Hmgb1 silencing on the expression of cartilage-specific genes   
To test the effect of Hmgb1 on the endogenous Matn1 expression in later steps of 
chondrogenesis, we performed silencing experiments in chondrogenic cell lines. The established 
human cell lines of either costal chondrocyte (C-28/I2) or chondrosarcoma origin (SW1353) are 
known to express cartilage-specific genes at a relatively low level compared to primary cultures 
[90, 100], whereas the chondrogenic marker gene expression of the RCS cell line is more similar 
to that of primary cultures [91]. In consistency with these data, we measured low mRNA levels 
relative to that of the S18 ribosomal protein mRNA in the human cell lines for MATN1 
(3.99x10−5 in C-28/I2 and 9.74x10−5 in SW1353 cells) and COL2A1 (4x10−5 in C-28/I2 and 
1x10−5 in SW1353 cells) (Fig. 14A and B). SOX9 expression level was also relatively low 
(7.16x10−2 in C-28/I2 and 4.74x10−2 in SW1353 cells), in sharp contrast to the highly elevated 
HMGB1 mRNA expression of the cells (1.59 in C-28/I2 and 1.46 in SW1353). RCS cells 
exhibited much higher relative mRNA levels for Col2a1 (8x10−2), Sox9 (2.51) and Matn1 
(3.56x10−4), whereas the Hmgb1 mRNA expression (1.39x10−1) was somewhat lower in the rat 
than in the human cell lines (Fig. 14C).  
As these cells lines differed from primary cultures in their high HMGB1 and low chondrogenic 
marker gene expressions [90, 91, 100], they provided excellent tools to test the hypothesis in 
silencing experiments whether the highly elevated HMGB1 expression as compared to Sox9 may 
contribute to the repression of the chondrogenic marker genes in later stage of chondrogenesis. 
We found that silencing of HMGB1 by 2.5-fold in C-28/I2 cells increased the expression level for 
MATN1 and COL2A1 by 3.6-4.3-fold and 4.9-5.3-fold, respectively (Fig. 14A). Silencing of 
HMGB1 by 2.4-2.7-fold in SW1353 cells increased the expression level for MATN1 and COL2A1 
by 9.6-32-fold and 10-13-fold, respectively (Fig. 14B). The activation was specific, as it affected 
neither the GAPDH nor the SOX9 mRNA levels (Fig. 12A and B). When silencing decreased the 
relative Hmgb1 mRNA level of RCS cells by 42-57-fold below the level of Sox9, the Matn1 and 
the Col2a1 mRNA levels increased by 59-74-fold and 9.3-15.9-fold, respectively (Fig. 14C). 
Hmgb1 silencing however did not significantly alter the Hprt or the Sox9 levels, suggesting a 
specific effect. 
We concluded that the highly elevated Hmgb1 expression compared to Sox9 can inhibit the 
cartilage protein gene expression in the established chondrogenic cell lines. In consistency with 
the repression of the Matn1 promoter activity by high dose of Hmgb1 in CEC culture (Fig. 11A), 
these data support the hypothesis that large abundance of Hmgb1/HMGB1 may interfere with the 




Fig. 14. Effect of Hmgb1 silencing on chondrogenic marker gene expression. (A- B) Established 
human chondrogenic cell lines were transfected with increasing amount of HMGB1 siRNA (100 pmoles 
and 200 pmoles for C-28/I2; 200 pmoles and 400 pmoles for SW1353). Parallel plates transfected with 
control siRNA (Ctrl) and GAPDH siRNA served as negative and positive controls, respectively, to 
indicate the efficiency and specificity of silencing. (C) Similar transfection experiments were performed 
in the RCS cell line using increasing amount (200 pmoles and 400 pmoles) of rat Hmgb1 siRNA and 
negative control siRNA. (A-C) Marker gene expression levels were determined by QRT-PCR and plotted 





Hmgb1 may inhibit the activation not only of Matn1 but of other cartilage protein genes as well 




5.15. Model for the unique transcriptional regulatory mechanisms of the Matn1 
 
Role of Sox trio and Nfi in the regulatory mechanism of Matn1 
Finally, we proposed a model for the unique transcriptional regulatory mechanisms of 
Matn1. This hypothesis is based on previous observations from our group [86, 88] that in vivo 
footprints were absent from the short promoter in the non expressing CEF and they gradually 
appeared in differentiating HDM culture, strongly suggesting that activation of Matn1 involves 
regulation at chromatin level. In fact, the Nfi sites of SI and SII were not occupied in vivo in 
CEF, albeit Nfi genes are expressed in CEF [89] and Nfi proteins can bind SI and SII from CEF 
extracts in EMSA and in vitro footprinting [87]. Based on their interaction with histones [60, 72], 
Nfi proteins may help to disrupt the nucleosome structure during Matn1 activation. 
According to our model, the special geometric arrangement of proximal elements may 
explain the unique regulation of Matn1, as it allows fine tuning of the promoter activity by L-
Sox5/Sox6 and Nfi, depending on their relative abundance to SOX9 (Fig. 15A). At the onset of 
chondrogenesis, binding of Sox and Nfi proteins might be needed to open the chromatin structure 
around the TATA (Fig. 15A, a and b). At early stage of chondrogenesis, when occupancy of the 
sites is low and SOX9 is expressed at high molar excess relative to L-Sox5/Sox6, SOX9 
preferably binds Pe1, and the Ine-bound L-Sox5/Sox6 synergizes with SOX9 by likely increasing 
its efficiency to bind Pe1 (Fig.15A,b). Pe1 likely plays central role in enhanceosome formation 
and in the SOX9-mediated promoter activation from Dpe1 and other distal elements but, due to 
the low abundance of transcription factors, the transcription activity is low in early proliferative 
chondroblasts (Fig. 15A, b). The promoter activity is highest in late proliferative chondroblasts, 
where the occupancy of Pe1 and other elements by SOX9 and other factors is optimal (Fig. 15A, 
c). At late stage, however, when the Sox trio level is elevated, large molar excess of L-Sox5/Sox6 
to SOX9 can decrease the transactivation by SOX9, possibly by competing with SOX9 for 
binding Pe1 and other elements (Fig. 15A, d). High occupancy of the Sox sites of Ine may even 
physically interfere with the recruitment of PIC to TATA. Overproduction of Nfi may also 
decrease the promoter activity due to competition between activator (e.g. Nfib) and repressor Nfi 








Fig. 15. Model for the role of Sox trio, Nfi and Hmgb1 factors in the unique transcriptional 
regulatory mechanisms of the Matn1. (A) Model for fine tuning of the promoter activity by the Sox trio 
and Nfi. Factor binding to DNA elements is schematized during Matn1 activation at the onset of 
chondrogenesis (a); in early (b) and late proliferative chondroblasts (c) at low and optimal occupancy of 
sites, respectively; and in late stage at high occupancy of the Sox (d) or Nfi sites (e). (B) Model for the 
regulation of the Matn1 promoter by Hmgb1 and Sox trio. Schematic illustration of factor binding to the 
conserved DNA elements at the onset of chondrogenesis (a), in early (b) and late proliferative 




Model for the interplay between Hmgb1 and Sox trio in the regulation of Matn1 
Based on the data, we also suggest a model for the contribution of Hmgb1 to the activation of 
the gene at the onset of chondrogenesis in amniotes (Fig. 15B). Hmgb1 is bound to the Dpe1, Pe1 
and Ine elements in fibroblasts and in committed mesenchyme (Fig. 15Ba). The architectural 
protein may fluidize the chromatin and bend the DNA to facilitate sequence-specific binding of 
the Sox trio to these DNA elements in early steps of chondrogenesis (Fig. 15Bb). The 
transcriptional activity of the gene is increasing as Hmgb1-binding is replaced by Sox9-binding 
and L-Sox5/Sox6 increases the transactivation by Sox9 in a dose-dependent synergistic manner 
in late proliferative chondroblasts (Fig. 15Bc). However, highly elevated Hmgb1 expression in 
transfected late proliferative chondroblasts or oncogenically transformed chondrogenic cells (e.g. 
chondrosarcomas), can repress the gene expression, likely because Hmgb1 present in large 






By dissecting and characterizing the Matn1 DNA elements and the interacting Sox, Nfi and 
Hmgb1 proteins, this dissertation gives new insight into the unique control mechanism that 
directs Matn1 expression into specific chondroblast developmental stages and distinct growth 
plate zones. In agreement with former reports from our group [86-89], the results presented in 
this dissertation uncover 1) fine tuning of the Sox9-mediated synergistic activation of the Matn1 
promoter by the dose of L-Sox5/Sox6; 2) fine tuning of the Sox9-mediated Matn1 promoter 
activation by the dose of Nfi proteins, which peaks in early stage of chondrogenesis; 3) the dose-
dependent modulation of the Sox trio-mediated synergistic Matn1 promoter activation by 
Hmgb1.  
Furthermore, based on the present and former data of our group, we proposed a model for the 
unique transcriptional regulation of Matn1 (Fig. 15). According to our model, the unique 
arrangement of the conserved DNA elements around the TATA box is an important part of this 
control mechanism, in which the Pe1-bound Sox9 plays a key role and mediates promoter 
enhancement from Dpe1. Chondroblast stage-specific regulation is achieved, because the Pe1-
bound Sox9 activity is finely tuned by the doses of L-Sox5/Sox6 and Nfi proteins bound to Ine 
and SI, respectively. The promoter activity is highest in late proliferative chondroblasts, where - 
due to the high expression level of chondrogenic Sox genes - the occupancy of the elements is 
optimal and the Ine-bound L-Sox5/Sox6 synergistically increases the transactivation by the Pe1-
bound Sox9, and the Sox9-mediated enhancement by Dpe1 is also optimal. In early stage of 
chondrogenesis, however, when the declining Hmgb1 level is higher than the raising Sox9 (Sox 
trio) level, Hmgb1 bound to the conserved Matn1 DNA elements may fluidize the chromatin, 
thereby facilitating the binding of Sox9 (Sox trio) to the promoter elements and helping the 
activation of the gene. Nfi proteins expressed in early proliferative chondroblasts may also 
promote the disruption of the nucleosome structure, participate in the assembly of the PIC and 
contribute to promoter activation. In hypertrophic chondrocytes or under disease conditions (e.g. 
inflammation, tumorigenesis), the highly elevated Hmgb1 level may inhibit the promoter activity 
by competing with Sox proteins for their binding to the conserved Matn1 control elements.  
Results presented in this dissertation confirm SOX9 binding to the Pe1 and Ine elements 
observed in previous in vitro assays [86, 88, 89] and support the important role of these elements 
in the cartilage-specific promoter activity in line with former observations in genomic 
footprinting and transgenic mice [86, 88, 89]. The CEC-specific in vivo footprints detected at the 
paired Sox motifs of Ine and Pe1 in genomic footprinting are likely due to cartilage-specific 
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binding of Sox proteins [86, 89]. ChIP analysis performed by our collaborating partner at the 
University of Debrecen also demonstrated cell type-specific in vivo binding of the Sox trio to the 
Matn1 control elements in human and rat chondrogenic cell lines. Furthermore, the presented 
mutational and functional data demonstrate the key role of the highly conserved Pe1 in the 
tansactivation by SOX9 and in SOX9-mediated enhancement from Dpe1 and distal elements. Ine 
is less conserved, but it is also needed for high transgene activity [88]. It rather seems to interact 
with L-Sox5/Sox6 in EMSA and forced-expression studies [88].  
Our model can give an explanation why the Matn1 short promoter plays a critical role in 
restricting cartilage-specific expression and how its activity is enhanced by distal elements in 
transgenic mice as it was observed earlier [86, 88]. Remarkably, the Matn1 short promoter could 
even restrict the activity of a powerful Sox-driven pan-chondrocytic Col2a1 heterologous 
enhancer to distal structures and specific growth plate zones. In line with our model, the 
transgene carrying the IneM1 mutation displayed very low activity in founder embryos, but this 
activity remained restricted to the columnar and prehypertophic growth plate zones, as with the 
TR70 transgene driven by the wild-type Matn1 long promoter [88]. 
Multiple copies of the conserved Dpe1 element fused to the short Matn1 promoter directed 
high, zonal and distal structure-specific transgene expression resembling to that directed by the 
long Matn1 promoter [88]. We concluded that Dpe1 working as an important enhancer element 
may account in large part for the high Sox-mediated enhancement of the Matn1 promoter in late 
proliferative chondroblasts for the following reasons. Dpe1 features three Sox sites binding 
SOX9 and L-Sox5 with opposite efficiency in vitro. It is needed for the high chondroblast stage-
specific promoter activity and transactivation by the Sox trio. Dpe1 elements can exert a Sox trio-
mediated, dose-dependent synergistic enhancement to the Matn1 and Col2a1 promoters in 
cultures.  
Our model is strengthened by the remarkable sequence and positional conservation of 
proximal (short) and distal DNA element observed by our collaborating partner in Debrecen (Fig. 
3) [86, 97] strongly suggesting an evolutionarily conserved transcriptional control in amniotes. 
Conservation of promoter and extragenic sequences in amniotes for other genes (e.g. Sox2) can 
reliably reflect their functional importance in development [40, 101]. Pe1 is most highly 
conserved among the Matn1 control elements [86]. Sox sites of Pe1 recognized preferably by 
SOX9 95 bp to 195 bp upstream of TATA are most crucial for the promoter activity, but those of 
Ine preferably binding L-Sox5/Sox6 around the transcription start sites are also important. Sox 
proteins bind the two paired Sox site of Ine in a cooperative manner [88]. Dpe1 located 1800-
2650 bp upstream of the promoter in various species is also highly conserved in amniotes [86]. 
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As it was shown for Sox trio binding to other cartilage-specific control elements [52, 84], Sox 
proteins may also bind the three paired Sox sites of Dpe1 in a cooperative manner. 
Cotransfection and forced expression assays and the analysis of various single and double 
mutants revealed that the SOX9-mediated activation of the long promoter as well as the 4XDpe1-
Col2a1 promoter construct is dose-dependently modulated by L-Sox5/Sox6 (Figs. 7).  
Such a high degree of sequence and positional conservation among chicken and mammalian 
orthologs has not been found for other cartilage genes. Conserved cartilage-specific element has 
been identified only in the far upstream enhancer of the mammalian orthologs of Acan, but it is 
not conserved in amniotes [84]. Although cartilage-specific control elements with functional Sox 
sites were found in varying location, e.g. in the first intron, far upstream promoter, 5’ 
untranslated or proximal promoter regions [52, 78, 84, 102-104], but they do not show similarity 
to the Matn1 control region. 
The transcriptional regulation of the Matn1 involves similar as well as different molecular 
mechanism as compared to other cartilage protein genes. The Sox trio likewise plays essential 
roles in transcriptional regulation of other cartilage-specific genes [52, 84, 104], but Matn1 is 
regulated differently by Sox trio than other cartilage ECM genes. One difference is that whereas 
Sox9 is sufficient for the activation of Col2a1, Acan and Crtl1, L-Sox5/Sox6 is also absolutely 
required for the activation of Matn1, as Matn1 mRNA was not detected in Sox5-/-;Sox6-/- mice 
[57]. Furthermore, we found that L-Sox5/Sox6 modulates the Matn1 promoter activation by 
SOX9 in a dose-dependent manner. This effect is likely due to unique set of conserved DNA 
elements that are capable of interacting with Sox proteins with different efficiency.  
In addition to the role of Sox trio, we also demonstrate the novel role of Nfi proteins in the 
gene regulation. We provide evidence that Nfi proteins also modulate the promoter activity and 
the SOX9-mediated transactivation in a dose-dependent manner. They increase the activation by 
SOX9 at low dose, but repress that at high dose. In agreement with the transient activation of Nfi 
genes during in vitro chondrogenesis in QRT-PCR, dominant negative mutation of Nfib 
interfered with chondrogenesis, while overexpression of the wild type Nfib increased the Sox9 
and Col2a1 expression [69], Nfi sites mediating this regulation however have not been identified 
yet. By extending novel results and previous data from our laboratory (EMSA, in vivo 
footprinting) [87], we provide evidence that, in addition to the Sox trio, Nfi proteins binding SI 
near TATA also play critical role in fine tuning and enhancement of the chondroblast stage-
specific activity of the Matn1 promoter. Based on genomic footprinting, the Nfi motifs of SI and 
SII are first occupied by in vivo bound transcription factors (Fig. 4), in line with the transient Nfi 
expression in early chondrogenesis [89]. 
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Our model is consistent with former observations [86, 88] that in vivo footprints were absent 
from the Matn1 short promoter in the non-expressing CEF and they gradually appeared in 
differentiating HDM culture, strongly suggesting that activation of Matn1 involves regulation at 
chromatin level. In fact, the Nfi sites of SI and SII were not occupied in vivo in CEF, albeit Nfi 
genes are expressed in CEF (Fig. 4D) [89] and Nfi proteins can bind SI and SII from CEF 
extracts in EMSA and in genomic footprinting [87]. Based on their interaction with histones and 
GTFs [60, 72], we can assume that Nfi proteins may help to disrupt the nucleosome structure and 
contribute to Matn1 activation. 
Furthermore, we reveal a previously unknown role for Hmgb1 in cartilage-specific gene 
regulation and in tumorigenesis. Hmgb1−/− mice were previously shown to suffer from 
pleiotropic defects. They die from hypoglycemia after birth, but survivors rescued by glucose 
treatment show severe developmental retardation and abnormalities in skeletal development 
[105]. Detailed analysis revealed a delay in endochondral ossification, largely because the lack of 
Hmgb1 secretion by hypertrophic chondrocytes impaired cartilage invasion by blood vessels, 
osteoclasts, and osteoblasts [8]. The size of the developing cartilaginous elements stained by 
alcian blue was also smaller in E16.5 Hmgb1−/− embryos than in wild-type littermates [8], 
suggesting that early steps of endochondral bone formation may also be affected by the mutation. 
Furthermore, Hmgb1 and Hmgb2 are needed for posterior digit development [8]. In line with in 
situ hybridizations by others [8, 48], we found that Hmgb1 expression declined during in vivo 
and in vitro chondrogenesis in inverse correlation with the activation of chondrogenic Sox and 
ECM genes, showing some overlap with raising Sox9 expression just before and at the time of 
Matn1 onset in early chondroblasts. Hmgb1 and SOX9 recognized the Dpe1, Pe1 and Ine 
elements with a reciprocal binding efficiency in vitro. In forced expression assays, optimal dose 
of Hmgb1 augmented the Sox trio-mediated activation of the Matn1 promoter in early 
chondrogenesis as well as the ectopic induction of the endogenous Matn1 in COS-7 cells by 2-3-
fold. Similar effect of Hmgb1 transfection was reported in other systems [45]. Hmgb1 could in 
large part compensate for the effect of mutations in Pe1 and in the 5’ Sox site of Ine in early 
chondrogenesis. In agreement with the slow occupancy of Sox motifs of the Pe1 and Ine 
elements of Matn1 in genomic footprinting in HDM cultures undergoing chondrogenesis in vitro 
[86, 89] ChIP experiments performed by our collaborating partner at the University of Debrecen 
revealed specific, but weak Sox9 and Sox5/Sox6 binding to the conserved Dpe1, Pe1 and Ine 
elements of Matn1 in rat and human chondrogenic cell lines. Hmgb1, however, exhibited much 
stronger binding to the same elements in agreement with the high Hmgb1 but low Matn1 and 
Col2a1 expression of these cells. Elevated Hmgb1 level may be due to the oncogenic 
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transformation of these cells, since Hmgb1 is upregulated in cancer cells and plays a role in 
tumor growth [47]. Silencing of HMGB1 specifically and markedly increased the expression of 
cartilage protein genes but not that of SOX9. When silencing decreased the Hmgb1 mRNA level 
below 2% of that of Sox9 in RCS cells, the Matn1 and Col2a1 expression increased even more 
dramatically, indicating that large abundance of Hmgb1 can inhibit the Sox9-mediated activation 
of cartilage protein genes. Hmgb1 overexpression in CEC also inhibited the Matn1 promoter 
activity, indicating a conserved mechanism in amniotes. Our data strongly suggests that, by 
modulating the access of Sox factors to evolutionarily conserved DNA elements, Hmgb1 can 
facilitate the synergistic activation of Matn1 by the Sox trio in early chondrogenesis, which turns 
to inhibition later. Thus Hmgb1 expressed in large abundance in terminally differentiated 
chondrocytes may compete with Sox factors for binding to the elements, thereby contributing to 
the decreased Matn1 expression during hypertrophy. Hmgb1 may also regulate other cartilage 
ECM genes by similarly modulating Sox factor binding to their control elements. Interestingly, 
HMGB1 was also reported to work as an alarmin and its level is high in the joints of patients 
with rheumatoid arthritis and juvenile idiopathic arthritis [106-108]. Therefore, based on our 
silencing experiments, we can assume that HMGB1 may similary inhibit the activity of MATN1 
and other cartilage ECM genes in such patients.  
The unique molecular mechanism described in this dissertation may facilitate the 
construction of growth plate zone-specific vectors and the development of biotechnological 




7. SUMMARY OF NOVEL RESULTS OF THE THESIS 
 
1) We monitored the marker gene expression by QRT-PCR in cultures representing subsequent 
stages of chondrogenesis. We observed an inverse correlation between the raising Sox9 (and 
L-Sox5) and the declining Hmgb1 mRNA levels, showing only a limited overlap at the time 
of Matn1 activation in early proliferative chondroblasts (at day 4 HDM culture). Transient 
activation of Nfi genes peaked in early proliferative chondroblasts (at day 4 HDM culture).  
 
Dose-dependent promoter activation by the Sox trio: 
2) We demonstrated in comparative EMSA experiment, that purified, GST-tagged Sox proteins 
can bind the conserved Matn1 DNA elements with varying affinity. SOX9 binds most 
strongly to Pe1, followed by the 3’ part of Dpe1, whereas L-Sox5 recognizes most efficiently 
the 5’ part of Dpe1. Ine exhibited the weakest binding to the Sox trio. 
3) Analysis of mutants in transient expression assays confirmed the important role of the Sox-
binding sites of Pe1 and Ine in the high chondroblast stage-specific activity of the long 
promoter and its transactivation by SOX9 and the Sox trio at both early and later stages of 
chondrogenesis. Point mutation of the Pe1 Sox motif dropped, while double mutation 
(Pe1M1-IneM2) disrupting each of the three paired Sox motifs of Pe1 and Ine, completely 
diminished the transactivation of the long promoter by the Sox trio in forced expression 
studies in COS-7 cells. Pe1M1-IneM2 double mutation also interfered with the short 
promoter activation by the heterologous Col2a1 cartilage-specific enhancer elements. 
4) We demonstrated that Dpe1 also plays an important role in the chondoblast stage-specific 
promoter activation. Deletion of Dpe1 robustly decreased the long promoter activity in 
transient expression assays and it highly interfered with the promoter activation by SOX9 and 
the Sox trio in cotransfection and forced expression assays, especially at early stage of 
chondrogensis.   
5) We confirmed in cotransfection experiments that Dpe1 can function as a cartilage-specific 
enhancer element in the non-expressing COS-7 culture, because four copies of Dpe1 worked 
efficiently in both orientations and the Dpe1 elements exerted a Sox trio-mediated dose-
dependent synergistic enhancement to the homologous and the heterologous Col2a1 
promoters.  
6) We provided evidence that, differing from other cartilage ECM genes, L-Sox5/Sox6 increased 
the transactivation of the Matn1 long promoter by SOX9 in a dose-dependent synergistic 
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manner. At low dose (early stage) L-Sox5/Sox6 synergized with SOX9 to activate the 
promoter, while at high dose (late stage) L-Sox5/Sox6 inhibited the activation by SOX9.  
 
Dose-dependent promoter activation by Nfi proteins: 
7) We demonstated in transient expression and forced expression experiments that the Nfi-
binding site of the SI element is also essential for the Matn1 promoter activity and its 
activation by SOX9. Point mutations in the Nfi motifs of the SI element dropped the long 
promoter activity even in early proliferative chondroblasts and hampered the promoter 
activation by SOX9 in cotransfection and forced expression assays. Mutation of the SI 
element also decreased the short promoter activation by the heterologous Col2a1 cartilage-
specific enhancer elements. 
8) We provided evidence in cotransfection and forced expression experiments that Nfi proteins 
can modulate the SOX9-mediated transactivation of Matn1 long promoter in a dose-
dependent manner. They increase the activation by SOX9 at low dose, while they decrease it 
at high dose. 
   
Dose-dependent modulation of the promoter activity by Hmgb1: 
9) In agreement with the QRT-PCR data, we found that Hmgb1 immunofluorescence dropped in 
the developing limbs of mouse embryos as chondrogenesis progressed, exhibiting a 
complementary pattern to that of Sox9 and Matn1 in overtly differentiated cartilaginous 
elements. Hmgb1 and Sox9 expression overlapped only in early chondroblasts at the time of 
the onset of Matn1. These data suggested that Hmgb1 may also contribute to the Matn1 
regulation in early steps of chondrogenesis.  
10) We demonstrated that Hmgb1 can bind to the conserved Matn1 DNA elements in vitro with 
opposite binding efficiency than SOX9. 
11) We found that Hmgb1 can increase the Matn1 promoter activity in cotransfection assays in 
early stages of chondrogenesis, but it rather inhibits the promoter activity at late stage.  
12) We provided evidence that Hmgb1 can increase the transactivation of the Matn1 promoter 
and even induce the endogenous Matn1 by forced expression of the Sox trio in the non-
expressing COS-7 cells.  
13) We concluded that the high HMGB1/Hmgb1 level relative to that of SOX9/Sox9 may inhibit 
the SOX9/Sox9 mediated activation of MATN1/Matn1 and other cartilage ECM genes in 
oncogene-transformed cell lines, because silencing of HMGB1/Hmgb1 in established human 
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(C-28/I2, SW1353) and mouse chondrogenic cell lines (RCS) robustly increased the 
MATN1/Matn1 and COL2A1/Col2a1 expression levels.   
 
Model for the transcriptional regulation of Matn1  
14) Finally, we proposed a model for the unique transcriptional regulatory mechanisms of Matn1. 
According to this model chondroblast stage-specific activation of Matn1 is achieved via a 
complicated interplay between Sox and Nfi proteins and the uniquely arranged conserved 
DNA elements. As a result, the transactivation of the Matn1 promoter by Sox9 is fine-tuned 
by the varying doses of L-Sox5/Sox6 and Nfi proteins relative to Sox9 during 
chondrogenesis. Furthermore, Hmgb1 can facilitate the promoter activation by the Sox trio at 
early stage of chondrogenesis by loosening up the nucleosome structure and promoting Sox 
factor binding. However at late stage or in tumors, the highly elevated Hmgb1 abundance 
relative to Sox9 may inhibit the Matn1 promoter activity by competing with the Sox trio for 
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9. SUPPLEMENTARY  
 




    Relative expression level  (2−ΔCτ)* 
           Definition Acc. No. 
Forward  
sequence 






Matn1 matrilin-1, cartilage matrix protein NM_001030375 tccacagggaccatgacc ctggccccttctgtgtca 3.4E-07 4.2E-06 9.3E-04 8.7E-03 
Matn3 matrilin 3 NM_205072 ctcagaagctgcaagcctatc gtgagtagaacgctggctca 8.9E-07 6.8E-06 8.1E-06 1.6E-04 
Matn4 matrilin 4 XM_425698 gacctggtgatggtgatcg caccagctcgaagttctgg 3.2E-06 2.4E-04 2.0E-03 1.6E-05 
Col2A1 collagen, type II, alpha 1 NM_204426 tgccgcgacatcaaactct ctggttcgggtcaatccagta 2.7E-03 2.3E-03 1.8E-02 4.1E-01 
Col6A1  collagen, type VI, alpha 1  NM_205107  gacatcatgctgttggtgga ggtggtgtcaaagttcttgct 1.2E-03 5.4E-04 4.9E-03 8.5E-04 
Col11A1  collagen, type XI, alpha 1, variant 2  XM_001231650  atccaatgggcactcagaac ggtggcagagctgcaagt 7.5E-04 8.9E-04 1.1E-02 5.0E-02 
Sox9  SRY (sex determining region Y)-box 9  NM_204281  catcgatttccgagacgtg tttcgatgttggagatgacg 2.3E-05 2.6E-04 6.6E-04 4.3E-03 
Sox6  SRY (sex determining region Y)-box 6  XM_421000  tgatcagcttacgggagca aggctgccagctttttctg 3.3E-05 1.4E-04 2.3E-04 3.7E-04 
Sox5 transcription factor L-Sox5-I  AJ626989 aacagccctcctcccaaaag ttgggtttggctgaaaggtt 1.5E-04 2.1E-04 2.0E-04 3.1E-03 
Hmgb1 high-mobility group box 1 NM_204902 gatccaaatgcaccgaaga tggacgaaactcagagcaaa 6.5E-03 4.5E-03 1.5E-03 2.0E-04 
Hmgn1 high-mobility group nucleosome binding domain 1 NM_205106 catcagtagaattgcttatctcgtg cattactcgtcaagaaatccaaca 4.7E-05 2.4E-04 1.5E-04 6.1E-05 
Nfia nuclear factor I-A NM_205273 tgatcagcttacgggagca caacagcgagttggtaagca 1.2E-03 9.2E-04 5.2E-03 9.0E-04 
Nfib nuclear factor I-B NM_205272 ctggtataaatctgcagaggtcttt gagatagttttgggtcttttgctg 5.9E-04 3.1E-04 8.2E-04 5.6E-05 
Nfic nuclear factor I-C NM_205271 gctctgcaattagccactttcc catcctgggtcaggcagaga 7.7E-04 7.5E-04 4.4E-03 3.4E-04 
Nfix nuclear factor I-X NM_205270 catcagtagaattgcttatctcgtg cattactcgtcaagaaatccaaca 1.0E-05 2.6E-06 5.8E-05 3.3E-06 
Gapdh glyceraldehyde-3-phosphate dehydrogenase NM_204305 cctctctggcaaagtccaag accatgtagttcagatcgatgaag     
28S rRNA  28S ribosomal RNA DQ018756 cccagaaaaggtgttggttg cttagcgggctccgactt     
18S rRNA  18S ribosomal RNA AF173612  gcaattattccccatgaacg atcaacgcgagcttatgacc     
 







Table S2. List of primers used in QRT-PCR reactions in forced expression and silencing experiments 
Gene 
symbol 
Definition Acc. No. Forward  sequence Reverse  sequence 
hMATN1 matrilin-1, cartilage matrix protein NM_002379 gaacagcgacggcaagac atgaggaagaccaggtcagtg 
hCOL2A1 collagen, type II, alpha 1 NM_033150 ccctggtcttggtggaaa cattggtccttgcattactcc 
hHMGB1 high-mobility group box 1 NM_002128 cattgagctccatagagacagc ggatctcctttgcccatgt 
hSOX9 SRY (sex determining region Y)-box 9 NM_000346.3 gtacccgcacttgcacaac tctcgctctcgttcagaagtc 
hGAPDH glyceraldehyde-3-phosphate dehydrogenase NM_204305 cctctctggcaaagtccaag accatgtagttcagatcgatgaag 
hRPS18 ribosomal protein S18 NM_022551 cttccacaggaggcctacac cgcaaaatatgctggaacttt 
rMatn1 matrilin-1, cartilage matrix protein NM_001006979 ttggcaagaagttgcagaaa cactatggactcacaggcaca 
rCol2A1 collagen, type II, alpha 1 NM_012929 ctggtacccctggaaatcct ccatctgggctgcaaagt 
rHmgb1 high-mobility group box 1 XM_003751117 gtaattttccgcgcttttgt tcatccaggactcatgttcagt 
rSox9 SRY (sex determining region Y)-box 9 XM_003750950.1 gtacccgcatctgcacaac ctcctccacgaagggtctct 
rHprt hypoxanthine-guanine phosphoribosyl transferase NM_012583 gaccggttctgtcatgtcg acctggttcatcatcactaatcac 
rRps18 ribosomal protein S18 NM_213557 cttccacaggaggcctacac cggggatcactagggacat 
mGapdh glyceraldehyde-3-phosphate dehydrogenase NM_001195426 gctcgtcatcaatggaagc ttgattttggagggatctcg 
h: Homo sapiens          r: Rattus norvegicus  m: Macaca mu 
 
